<SEC-DOCUMENT>0001213900-26-034716.txt : 20260326
<SEC-HEADER>0001213900-26-034716.hdr.sgml : 20260326
<ACCEPTANCE-DATETIME>20260326160846
ACCESSION NUMBER:		0001213900-26-034716
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20260325
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260326
DATE AS OF CHANGE:		20260326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Health In Tech, Inc.
		CENTRAL INDEX KEY:			0002019505
		STANDARD INDUSTRIAL CLASSIFICATION:	INSURANCE AGENTS BROKERS & SERVICES [6411]
		ORGANIZATION NAME:           	02 Finance
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42449
		FILM NUMBER:		26798225

	BUSINESS ADDRESS:	
		STREET 1:		701 S. COLORADO AVE
		STREET 2:		SUITE 1
		CITY:			STUART
		STATE:			FL
		ZIP:			34994
		BUSINESS PHONE:		888-373-0333

	MAIL ADDRESS:	
		STREET 1:		701 S. COLORADO AVE
		STREET 2:		SUITE 1
		CITY:			STUART
		STATE:			FL
		ZIP:			34994
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0283456-8k_health.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:HIT="http://healthintech.com/20260325">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_HIT_healthintech.com_20260325 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20260325_20260325 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0002019505 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000004" name="dei:EntityCentralIndexKey">0002019505</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hit-20260325.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-03-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002019505</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-25</xbrli:startDate>
        <xbrli:endDate>2026-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20260325__20260325_zmM31Lsqo3o4"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Current Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--DocumentPeriodEndDate_c20260325__20260325_zoRsgAWYJRb6"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 25, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20260325__20260325_zqq2BdyzO43a"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000011" name="dei:EntityRegistrantName">Health In Tech, Inc.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20260325__20260325_zgg6Tr9ATssd"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20260325__20260325_zPeyspJzWyz"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000013" name="dei:EntityFileNumber">001-42449</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20260325__20260325_zS9jvF9VBMQg"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000014" name="dei:EntityTaxIdentificationNumber">87-3545722</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20260325__20260325_z7SyLTxYRCnc"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000015" name="dei:EntityAddressAddressLine1">701 S. Colorado Ave</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20260325__20260325_zAEwkujqU4Pd"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 1</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20260325__20260325_zPy3JOVGwpO"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000017" name="dei:EntityAddressCityOrTown">Stuart</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20260325__20260325_zH5sT2b8Vohj"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000018" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b></p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressPostalZipCode_c20260325__20260325_z48yfcNEMhX"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000019" name="dei:EntityAddressPostalZipCode">34994</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_900_edei--CityAreaCode_c20260325__20260325_zX5f4lHUpcTi"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000020" name="dei:CityAreaCode">888</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20260325__20260325_zF4efFkJzSFb"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000021" name="dei:LocalPhoneNumber">373-0333</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--WrittenCommunications_c20260325__20260325_zLoe3oup5BPa"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SolicitingMaterial_c20260325__20260325_zY60cOlQHns9"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementTenderOffer_c20260325__20260325_zlV8vsE5G4A"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20260325__20260325_zbTzAk5BWv94"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20260325__20260325_zq0DOIWXfXcd"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000026" name="dei:Security12bTitle">Class A Common Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20260325__20260325_zIXTPSLZJiJf"><ix:nonNumeric contextRef="AsOf2026-03-25" id="Fact000027" name="dei:TradingSymbol">HIT</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The <span id="xdx_90B_edei--SecurityExchangeName_c20260325__20260325_zkX090RSHMLk"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Nasdaq Capital Market)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20260325__20260325_zpkT3gZCBtva"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityExTransitionPeriod_c20260325__20260325_zgKQL1E6x2Xk"><ix:nonNumeric contextRef="AsOf2026-03-25" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2026, Health In Tech, Inc., a Nevada
corporation (the &#8220;Company&#8221;), announced that it has entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;)
with certain accredited investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;) relating to a private
investment in public equity financing (the &#8220;PIPE&#8221;) for an aggregate of 5,600,000 shares of its common stock, par value $0.001
per share (the &#8220;Shares&#8221;). The gross proceeds to the Company from the PIPE are expected to be approximately $7.0 million before
deducting placement agent fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from
the PIPE to expand sales distribution, advance technology development, support new product development, and for general corporate purposes
and working capital. The transaction is expected to close on or about March 27, 2026, subject to the satisfaction of customary closing
conditions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Purchase Agreement, the
Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with each Purchaser. Pursuant to
the Registration Rights Agreement, and subject to certain exceptions contained therein, the Company is required to file a resale registration
statement (the &#8220;Registration Statement&#8221;) with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) to register
the Shares for resale within thirty (30) calendar days of the date of the Registration Rights Agreement, to use its commercially reasonable
efforts to have such Registration Statement declared effective within the time period set forth in the Registration Rights Agreement,
and to keep the Registration Statement effective until the date that all registrable securities covered by the Registration Statement
(i) have been sold, thereunder or pursuant to Rule 144 promulgated under the Securities Act (as defined below) (&#8220;Rule 144&#8221;),
or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to
be in compliance with the current public information requirement under Rule 144.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement and the Registration Rights
Agreement contain representations, warranties, covenants, indemnification and other provisions customary for transactions of this nature.
The representations, warranties, covenants and agreements contained in the Purchase Agreement and the Registration Rights Agreement reflect
negotiations between the parties to the Purchase Agreement and the Registration Rights Agreement and are not intended as statements of
fact to be relied upon by stockholders, or any individual or other entity other than the parties. In particular, the representations,
warranties, covenants and agreements in the Purchase Agreement and the Registration Rights Agreement may be subject to limitations agreed
by the parties, including having been modified or qualified by certain confidential disclosures that were made between the parties in
connection with the negotiation of the Purchase Agreement and Registration Rights Agreement, and having been made for purposes of allocating
risk among the parties rather than establishing matters of fact. In addition, the parties may apply standards of materiality in a way
that is different from what may be viewed as material by investors. As such, the representations and warranties in the Purchase Agreement
and the Registration Rights Agreement may not describe the actual state of affairs at the date they were made or at any other time and
you should not rely on them as statements of fact. Moreover, information concerning the subject matter of the representations and warranties
may change after the date of the Purchase Agreement and the Registration Rights Agreement, and unless required by applicable law, the
Company undertakes no obligation to update such information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also entered into a placement agency
agreement (the &#8220;Placement Agency Agreement&#8221;) with Craig-Hallum Capital Group LLC, as the sole placement agent (the &#8220;Placement
Agent&#8221;), dated March 25, 2026, pursuant to which the Placement Agent agreed to serve as the placement agent in connection with the
PIPE in consideration for a cash placement fee and the reimbursement of certain out of pocket expenses, including those of its legal counsel.
In addition, the Placement Agency Agreement requires the delivery of customary lock-up agreements from the directors and officers of the
Company from the date of execution of the Placement Agency Agreement until 60 days after the effectiveness of the resale registration
statement for the Shares, with such lock-up agreements containing customary carve-out provisions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shares are being issued pursuant to the exemption
from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Section 4(a)(2)
of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder because, among other things, the transaction did not involve
a public offering, each Purchaser represented that it is an &#8220;accredited investor&#8221; and is purchasing the Shares as principal
for its own account and not with a view to or for distributing or reselling the Shares and the Company took appropriate measures to restrict
the transfer of the Shares. The Shares were offered without any general solicitation by the Company or its representatives. Shares have
not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration
with the Securities and Exchange Commission (the &#8220;SEC&#8221;) or an applicable exemption from the registration requirements of the
Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing descriptions of the Purchase Agreement,
the Registration Rights Agreement and the Placement Agency Agreement are qualified in their entirety by reference to the full text of
each document, copies of which are filed hereto as Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information under
Item 1.01 of this Current Report on Form 8-K related to the Shares is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K shall not constitute
an offer to sell or the solicitation of an offer to buy nor shall there be any offer, solicitation or sale of the Shares in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01 Regulation FD Disclosure. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2026, the Company issued a press
release announcing the PIPE, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information
furnished in Exhibit 99.1 hereto shall not be considered &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be incorporated
by reference into future filings by the Company under the Securities Act or under the Exchange Act, unless the Company expressly sets
forth in such future filings that such information is to be considered &#8220;filed&#8221; or incorporated by reference therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Forward-Looking Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this Current Report on Form
8-K are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements may include estimates or expectations about Health In Tech&#8217;s possible or assumed operational
results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential
growth opportunities. In some cases, forward-looking statements can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;should,&#8221; &#8220;design,&#8221; &#8220;target,&#8221; &#8220;aim,&#8221; &#8220;hope,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221;
&#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;goal,&#8221; or other words that convey the uncertainty
of future events or outcomes. These statements relate to future events or to Health In Tech&#8217;s future financial performance, and
involve known and unknown risks, uncertainties and other factors that may cause Health In Tech&#8217;s actual results, levels of activity,
performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech&#8217;s control and which could, and likely
will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although not all risks
and uncertainties, that could cause the Company&#8217;s actual results to differ materially from those presented in its forward-looking
statements are set forth in the &#8220;Risk Factors&#8221; section in the Company&#8217;s Annual Report on Form 10-K, its Quarterly Reports
on Form 10-Q, and all of its other filings with the SEC, as such risks, uncertainties and other important factors may be updated from
time to time in the Company&#8217;s subsequent reports. Any forward-looking statement reflects Health In Tech&#8217;s current views with
respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech&#8217;s operations,
results of operations, growth strategy and liquidity.<b>&#160;</b>Health In Tech undertakes no obligation to update any forward-looking
statements, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; vertical-align: bottom; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028345601ex10-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement, dated as of March 25, 2026, by and among Health In Tech, Inc., Craig-Hallum Capital Group LLC and the purchasers party thereto. </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028345601ex10-2.htm"><span style="font-size: 10pt">Registration Rights Agreement, dated as of March 25, 2026, by and among Health In Tech, Inc., Craig-Hallum Capital Group LLC and the holders party thereto. </span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028345601ex10-3.htm"><span style="font-size: 10pt">Placement Agency Agreement, dated as of March 25, 2026, 2025, by and between Health In Tech, Inc. and Craig-Hallum Capital Group LLC.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028345601ex99-1.htm"><span style="font-size: 10pt">Press release dated March 25, 2026.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 10pt">Dated: March 26, 2026</span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 10pt">HEALTH IN TECH, INC.</span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; padding-bottom: 1pt; width: 35%"><span style="font-size: 10pt"><i>/s/ Tim Johnson</i></span></td>
    <td style="white-space: nowrap; width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">Name:&#160; </span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Tim Johnson</span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-size: 10pt">Title: </span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdsKgkAQhp/Adxj2WkotDbxMKiKLEIlul5xiSXdkdjv4SL1lqxINA3P6v/mF8MWG1qpGhvOyyKHEpq2lRSjwioz6gk6RbXcpuFrgTRnLUtth/IEZOQYdk0xi6faD8qkMVikEs2kUT6PENel8Ace98Pp7RvqqKtRWyRqkruDI1LJCK7kbP5TyTZqabnA6IRtFOoVwEoznD0RBGMGBnvJFfDeQ55nw/CE8sWF6tE61elvUPQmrGhtnZ0b6n94X0F1KZA== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea028345601ex10-1.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT, DATED AS OF MARCH 25, 2026, BY AND AMONG HEALTH IN TECH, INC., CRAIG-HALLUM CAPITAL GROUP LLC AND THE PURCHASERS PARTY THERETO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of March 25, 2026, between Health In Tech, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature page hereto (including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and
collectively, the &ldquo;Purchasers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities
Act contained in Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder as to the Shares of Stock (as defined below), the
Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.1&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Definitions</U></FONT>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Applicable Laws</U>&rdquo;
means all United States (federal, state and local), rules, regulations, codes, treaties, or guidance applicable to the Company or the
Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close; <U>provided</U>, <U>however</U>,
for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;,
&ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for
wire transfers) of commercial banks in the City of New York generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s obligations
to deliver the Shares, in each case, have been satisfied or waived, but (a) in no event earlier than the first Trading Day following the
date hereof and (b) in no event later than the fifth Trading Day after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the Class A common stock of the Company, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred shares, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Counsel</U>&rdquo;
means Loeb &amp; Loeb LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure Time</U>&rdquo;
means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight
(New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and
(ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later
than 9:01 a.m. (New York City time) on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation Date</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt Issuance</U>&rdquo;
means the issuance of (a) shares of Common Stock, restricted stock awards or options to employees, consultants, officers or directors
of the Company pursuant to any share or option plan or arrangement disclosed in the SEC Reports on the date of this Agreement, and (b)
securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement,
provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with share splits or combinations)
or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions and the payment of
contractor invoices in the ordinary course of business approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein,
and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental Representations</U>&rdquo;
means the representations and warranties made by the Company in Sections 3.1(a) (Subsidiaries), 3.1(b) (Organization and Qualification),
3.1(c) (Authorization; Enforcement), 3.1(d) (No Conflicts), 3.1(e) (Filings, Consents and Approvals), 3.1(f) (Issuance of the Securities;
Registration), 3.1(g) (Capitalization), 3.1(h) (SEC Reports; Financial Statements), 3.1(u) (Investment Company), 3.1(w) (Listing and Maintenance
Requirements), 3.1(z) (No Integrated Offering), 3.1(nn) (Other Covered Persons), 3.1(oo) (Private Placement), 3.1(pp) (No General Solicitation)
and 3.1(qq) (No Disqualification Events).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual Property
Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issuer Covered Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(qq).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend Removal Date</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Adverse
Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Permits</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share Purchase
Price</U>&rdquo; equals $1.25, subject to adjustment for reverse and forward share splits, share dividends, share combinations and
other similar transactions of the shares of Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement Agent</U>&rdquo;
means Craig-Hallum Capital Group LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement Agency
Agreement</U>&rdquo; means that certain placement agency agreement dated as of the date hereof between the Company and the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition) pending or, to the Company&rsquo;s knowledge, threatened in writing against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser Party</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration Rights
Agreement</U>&rdquo; means the Registration Rights Agreement, date on or about the date hereof, among the Company and the Purchasers,
in the form of <U>Exhibit C</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration Statement</U>&rdquo;
means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering the resale by the
Purchasers of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required Approvals</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock of the Company issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short Sales</U>&rdquo;
means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription Amount</U>&rdquo;
means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below such Purchaser&rsquo;s
name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in
immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in Exhibit 21.1 to the Annual Report on Form 10-K filed by the Company on March 25, 2026
for the year ended December 31, 2025, and any subsidiary subsequently disclosed in the SEC Reports, and shall, where applicable, also
include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock are listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, or the
OTCQX Market (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Documents</U>&rdquo;
means this Agreement, the Registration Rights Agreement, the Placement Agency Agreement, all exhibits and schedules thereto and hereto
and any other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Transhare Corporation, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock are then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or, if such date is not a Trading
Day, the nearest preceding Trading Day) on the Trading Market on which the Common Stock are then listed or quoted as reported by Bloomberg
L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then
listed or quoted on a Trading Market but the Common Stock is then quoted on the OTCQB Market, the volume weighted average price of the
Common Stock for such date (or if such date is not a Trading Day, the nearest preceding Trading Day) on the OTCQB Market, (c) if the Common
Stock is not then listed or quoted for trading on a Trading Market or the OTCQB Market but prices for the Common Stock are then reported
on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock reported at 4:02 p.m. (New York City time) on such date (or if such date is not a Trading Day, the nearest
preceding Trading Day), or (d) in all other cases, the fair market value of an Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Shares then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.1&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Closing</U></FONT>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $5,600,000 of Shares (at the Per Share Purchase Price) as determined pursuant
to Section 2.2(a)(vi). Each Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds
equal to such Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and the Company
shall deliver to each Purchaser its Shares as determined pursuant to Section 2.2, and the Company and each Purchaser shall deliver the
other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing shall occur at a location as the parties hereto shall mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.2&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Deliveries</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser (and, as applicable, the Placement
Agent) the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">this Agreement duly executed by the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a legal opinion of Company Counsel in a form reasonably acceptable to each Purchaser and the Placement
Agent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company
letterhead and executed by the Company&rsquo;s Chief Executive Officer or Chief Financial Officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">the Company shall have provided each Purchaser and the Placement Agent with a certificate executed by
the Chief Financial Officer of the Company, dated as of such date, in form and substance satisfactory to each Purchaser and the Placement
Agent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">on the date of this Agreement and on the Closing Date, as the case may be, MaloneBailey LLP shall have furnished to the Placement
Agent, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Placement Agent, in
form and substance reasonably satisfactory to the Placement Agent, containing statements and information of the type customarily included
in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and certain financial information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver
on an expedited basis, (i) certificates evidencing the number of Shares contemplated to be issued pursuant to the signature page of each
Purchaser attached hereto, or (ii) at the election of each Purchaser, evidence of the issuance of such Purchaser&rsquo;s Shares as held
in restricted book-entry form by the Transfer Agent, which evidence shall be reasonably satisfactory to each applicable Purchaser, in
each case, registered in the name of such Purchaser; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">on the date hereof, the duly executed Lock-Up Agreements (as defined in the Placement Agency Agreement)
shall have been delivered to the Placement Agent; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">the Registration Rights Agreement duly executed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;On
or prior to the Closing Date (unless otherwise set forth below), each Purchaser shall deliver or cause to be delivered to the Company
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">this Agreement duly executed by such Purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Registration Rights Agreement duly executed by such Purchaser; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">such Purchaser&rsquo;s Subscription Amount by wire transfer or certified check to the account specified
in the wire instructions delivered pursuant to Section 2.2(a)(iii).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.3&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Closing
Conditions</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the accuracy in all material respects (or, to the extent representations or warranties are qualified by
materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the
Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the
Closing Date shall have been performed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the accuracy in all material respects (or, to the extent representations or warranties are qualified by
materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the
Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing
Date shall have been performed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by
the Commission or the Company&rsquo;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally
as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities
whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United
States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case,
in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Shares at the Closing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.1&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Representations
and Warranties of the Company</U></FONT>. Except as set forth in the SEC Reports (other than as to the Fundamental Representations, which
are not so qualified), the Company hereby represents and warrants to each of the Investors that the statements contained in this <U>Section
3.1</U> are true and correct as of the date of this Agreement and as of the Closing Date (except for the representations and warranties
that speak as of a specific date, which shall be made as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth on the SEC Reports. The Company owns, directly or indirectly,
all of the capital share or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in
the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation or other organizational or charter
documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation
or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result
in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect
on the results of operations, assets, business, or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a
whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;); provided that a change in
the market price or trading volume of the Common Stock alone shall not be deemed, in and of itself, to constitute a Material Adverse Effect.
No Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such
power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s shareholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby and thereby do not
and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of incorporation
or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or
any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or
Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably
be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant
to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Registration Statement pursuant to Section 4.16 of this Agreement,
(iii) application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required
thereby, and (iv) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities
laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Issuance
of the Securities; Registration</U>. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company
has reserved from its duly authorized capital shares the maximum number of shares of Common Stock issuable pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>Capitalization</U>.
The Company&rsquo;s disclosure of its authorized, issued and outstanding capital stock in the SEC Reports containing such disclosure was
accurate in all material respects as of the date indicated in such SEC Reports. The Company has not issued any capital shares since its
most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee share options under the Company&rsquo;s
share option plans, the issuance of shares of Common Stock to employees, consultants and directors pursuant to the Company&rsquo;s equity
incentive plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently
filed periodic report under the Exchange Act. Except as a result of the purchase and sale of the Shares and as set forth in the SEC Reports,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock or the capital share of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or
capital shares of any Subsidiary. Except as set forth in the SEC Reports, the issuance and sale of the Shares will not obligate the Company
or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers and the Placement Agent)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any
of such securities. Except as set forth in the SEC Reports<U>,</U> there are no outstanding securities or instruments of the Company or
any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an
issuance of securities by the Company or any Subsidiary. Except as set forth in the SEC Reports<U>,</U> there are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any share appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding capital shares of the Company are duly authorized, validly issued, fully paid and nonassessable,
have been issued in compliance with all applicable federal and state securities laws, and none of such outstanding shares was issued in
violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further
approval or authorization of any shareholder, the Board of Directors or others is required for the issuance and sale of the Shares. There
are no shareholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital shares to which
the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;<U>SEC
Reports; Financial Statements</U>. Except as disclosed in the SEC Reports, the Company has filed all reports, schedules, forms, statements
and other documents required to be filed by the Company under the Securities Act and Exchange Act, including pursuant to Section 13(a)
or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together
with the Company&rsquo;s Registration Statement on Form S-1 (Registration No. 333-281853) as amended and supplemented, being collectively
referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing
and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied
in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports,
when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has
never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports
complied in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect
thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with U.S. generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in
a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables
and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be
reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company
has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital shares and (v) the Company
has not issued any equity securities to any officer, director or Affiliate, except pursuant to a Company equity compensation or shares
option plans disclosed in the SEC Reports. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Shares contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their
respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the
Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at
least one (1) Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;<U>Litigation</U>.
There is no material action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;).
None of the Actions set forth in the SEC Reports (i) adversely affects or challenges the legality, validity or enforceability of any of
the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result
in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor, to the Company&rsquo;s knowledge, any director or officer thereof,
is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
of breach of fiduciary duty, which could result in a Material Adverse Effect. There has not been, and to the knowledge of the Company,
there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer
of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement
filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where
the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all applicable federal, state, local and foreign laws relating to
pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii),
the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each
case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii) Liens for the payment of federal,
state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither
delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except where the failure
to be in compliance would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)&nbsp;<U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.
Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC
Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the
rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the
Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and
value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license
rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any
rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary for companies of the Company&rsquo;s size and in the businesses in which the Company and the Subsidiaries
are engaged, including, but not limited to, directors and officers insurance coverage at least equal to $5 million in the aggregate. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant
increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)&nbsp;<U>Transactions
With Affiliates and Employees</U>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company,
none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, shareholder,
member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii)
reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including share option agreements under
any share option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as
of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially
affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)&nbsp;<U>Certain
Fees</U>. Except pursuant to the Placement Agency Agreement, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect
to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may
be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not be or be
an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the
Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;<U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any
securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)&nbsp;<U>Listing
and Maintenance Requirements</U>. The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of
the shares of Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice
from any Trading Market on which the Common Stock are or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock are currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current
in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s articles of incorporation (or similar charter documents) or the laws of its state of
incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their respective
obligations or exercising their respective rights under the Transaction Documents, including without limitation, as a result of the Company&rsquo;s
issuance of the Shares and the Purchasers&rsquo; ownership of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents and certain preliminary
unaudited financial information, the Company confirms that neither it nor any other Person acting on its behalf has provided the Purchasers
or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which
is not otherwise disclosed in the SEC Reports. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company
during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or
has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth
in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares to be integrated
with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the Shares under the
Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company
are listed or designated, which, if integrated, will not be obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)&nbsp;<U>Solvency</U>.
The SEC Reports set forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary (excluding
any unpaid interest thereon accrued since the Evaluation Date), or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000
(other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases
required to be capitalized in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)&nbsp;<U>Tax Status</U>.
Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect,
the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and
franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations
and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the
periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign
or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)
failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the
Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)&nbsp;<U>Accountants</U>.
The Company&rsquo;s independent registered public accounting firm is set forth in the SEC Reports. To the knowledge and belief of the
Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion
with respect to the financial statements to be included in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ending December
31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)&nbsp;<U>Acknowledgment
Regarding Purchaser&rsquo;s Purchase of Securities</U>. The Company acknowledges and agrees that each Purchaser is acting solely in the
capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company
further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective
representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental
to the Purchasers&rsquo; purchase of the Shares. The Company further represents to each Purchaser that the Company&rsquo;s decision to
enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)&nbsp;<U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(e) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked
by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company,
or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Shares for any specified term; (ii) past
or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo;
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which
any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the shares of Common Stock,
and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities (in material
compliance with Applicable Laws) at various times during the period that the Shares are outstanding, and (z) such hedging activities (if
any) could reduce the value of the existing shareholders&rsquo; equity interests in the Company at and after the time that the hedging
activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any
of the Transaction Documents. Notwithstanding anything to the contrary, nothing in this Agreement shall be deemed to permit any Purchaser
to engage in any transaction in violation of Regulation M under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)&nbsp;<U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Shares,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company,
other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)&nbsp;<U>Cybersecurity</U>.
(i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information
technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;IT Systems and Data&rdquo;)
and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are
presently in compliance with all Applicable Laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and
maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster
recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;<U>Share
Option Plans</U>. Each share option granted by the Company under the Company&rsquo;s share option plans was granted (i) in accordance
with the terms of the Company&rsquo;s share option plans and (ii) with an exercise price at least equal to the fair market value of the
shares of Common Stock on the date such share option would be considered granted under GAAP and applicable law. No share option granted
under the Company&rsquo;s share option plans has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, share options prior to, or otherwise knowingly coordinate the grant of share options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)&nbsp;<U>Other
Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that
has been or will be paid (directly or indirectly) remuneration for solicitation of the Purchasers in connection with the sale of any Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo)&nbsp;<U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Shares by the Company to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp)&nbsp;<U>No General
Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Shares by any form
of general solicitation or general advertising. The Company has offered the Shares for sale only to each Purchaser as an &ldquo;accredited
investor&rdquo; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(qq)&nbsp;<U>No Disqualification
Events</U>. With respect to the Shares to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the
Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in
the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities, calculated on
the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company
in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo;
disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except
for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer
Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations
under Rule 506(e), and has furnished to each Purchaser a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(rr)&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.2&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Representations
and Warranties of the Purchasers</U></FONT>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case such representation
or warranty shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Shares pursuant to the Registration Statement or otherwise in compliance with applicable
federal and state securities laws). Such Purchaser understands that the Shares are &ldquo;restricted securities&rdquo; and have not been
registered under the Securities Act or any applicable state securities law and is acquiring the Shares hereunder in the ordinary course
of its business. Such Purchaser is acquiring such Shares as principal for his, her or its own account and not with a view to or for distributing
or reselling such Shares or any part thereof in violation of the Securities Act or any applicable state securities law, has no present
intention of distributing any of such Shares in violation of the Securities Act or any applicable state securities law and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares in violation
of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&rsquo;s right
to sell such Shares pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Shares, it was, and as of the date hereof it is, and it will be either: (i) an
&ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities
Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A(a) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Shares and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares and
the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition, results of
operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement
Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Shares nor
is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation
as to the Company or the quality of the Shares and the Placement Agent and any Affiliate may have acquired non-public information with
respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Shares to such Purchaser,
neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received
a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser
is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and
the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of
such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Shares covered by this Agreement. Other than to other Persons party
to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners, legal
and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it
in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance
of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any actions with respect
to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities of the Company in order
for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>General
Solicitation</U>. Such Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other communication
regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar
or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;<U>No
Disqualification Events</U>. With respect to the Shares to be offered and sold hereunder in reliance on Rule 506 under the Securities
Act, such Purchaser at the time of sale is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i)
to (viii) under the Securities Act, except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.1&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Removal
of Legends</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;The
Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of any such Shares
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of
counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares under the Securities
Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and the Registration
Rights Agreement and shall have the rights and obligations of a Purchaser under this Agreement and the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;The
Purchasers agrees to the imprinting, so long as is required by this Section 4.1, of a legend on each of the Shares in substantially the
following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">THIS SECURITY HAS NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT
IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Shares to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under
the terms of such arrangement, such Purchaser may transfer pledged or secured any of the Shares to the pledgees or secured parties. Such
a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party
or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s
expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of any of the Shares may reasonably
request in connection with a pledge or transfer of such Shares, including, if the Shares are subject to registration pursuant to the Registration
Rights Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other
applicable provision of the Securities Act to appropriately amend the list of Selling Shareholders (as defined in the Registration Rights
Agreement) thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;Certificates
evidencing the Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration
statement covering the resale of such security is effective under the Securities Act, or (ii) following any sale of such Shares pursuant
to Rule 144, or (iii) if such Shares are eligible for sale under Rule 144, or (iv) if such legend is not required under applicable requirements
of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission), subject in the case
of clauses (ii), (iii) and (iv) to receipt from the Purchaser by the Company and the Transfer Agent of customary representations reasonably
acceptable to the Company and the Transfer Agent in connection with such request. The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent or a Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder,
or if requested by such Purchaser, respectively. If such Shares may be sold under Rule 144 or if such legend is not otherwise required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the
Commission) then such Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer
required under this Section 4.1(c), the Company will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer
Agent of a certificate representing Shares, as applicable, issued with a restrictive legend (such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;),
deliver or cause to be delivered to such Purchaser a certificate (or account statement from the Transfer Agent) representing such shares
that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the
Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Shares subject to legend removal hereunder shall
be transmitted by the Transfer Agent to each applicable Purchaser by crediting the account of such Purchaser&rsquo;s prime broker with
the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means
the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the
shares Common Stock as in effect on the date of delivery of a certificate representing Shares issued with a restrictive legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;In
addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Shares (based on the VWAP of the shares of Common Stock on the date such Shares are submitted
to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing
to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date
until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered)
to a Purchaser by the Legend Removal Date a certificate representing the Shares so delivered to the Company by such Purchaser that is
free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares
of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock,
that such Purchaser anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of such
Purchaser&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common
Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;)
over the product of (A) such number of Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied
by (B) the lowest closing sale price of the shares of Common Stock on any Trading Day during the period commencing on the date of the
delivery by such Purchaser to the Company of the applicable Shares (as the case may be) and ending on the date of such delivery and payment
under this Section 4.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.2&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Furnishing
of Information</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;Until
the time that the Purchasers no longer own any of the Shares the Company covenants to timely file (or obtain extensions in respect thereof
and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange
Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;At
any time during the period commencing from the date hereof and ending at such time that all of the Shares (assuming cashless exercise)
may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c)
or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy
any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s
other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason
of any such delay in or reduction of its ability to sell the Shares, an amount in cash equal to two percent (2.0%) of the aggregate Subscription
Amount with respect to the Shares pursuant to Rule 144. The payments to which the Purchasers shall be entitled pursuant to this Section
4.2(b) are referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo; Public Information Failure Payments shall be
paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii)
the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event
the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear
interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s
right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available
to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.3&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Integration</U></FONT>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2 of the Securities Act) that would be integrated with the offer or sale of the Shares in a manner that would require the registration
under the Securities Act of the sale of the Shares or that would be integrated with the offer or sale of the Shares for purposes of the
rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.4&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Securities
Laws Disclosure; Publicity</U></FONT>. The Company shall (a) by the Disclosure Time issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act and (iii) unless otherwise disclosed by the Disclosure Time by the Company
via a broadly disseminated press release and/or 8-K, issue a press release, or include in the press release in the foregoing clause (a),
disclosing all material non-public information concerning the Company disclosed to the Purchasers. From and after the issuance of such
press release(s), the Company represents to the Purchasers, as of the Closing, that it shall have publicly disclosed all material, non-public
information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors,
employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance
of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and
each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except that if such disclosure
is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a) as required by federal securities law in connection with (i) any registration statement contemplated by the Registration
Rights Agreement and (ii) the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required
by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted
under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.5&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Shareholder
Rights Plan</U></FONT>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Shares under the
Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.6&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Non-Public
Information</U></FONT>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes,
material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information and agreed
with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the
foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or
any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser
without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality
to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to
the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the
basis of, such material, non-public information, provided that such Purchaser shall remain subject to applicable law. To the extent that
any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such material non-public information with the Commission pursuant to a Report
on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions
in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.7&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Use
of Proceeds</U></FONT>. The Company shall use the net proceeds from the sale of the Shares hereunder for sales distribution, technology
development, new products and working capital and general corporate purposes and shall not use such proceeds in violation of FCPA or OFAC
regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.8&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Indemnification
of Purchaser</U></FONT>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court
costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of
or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any shareholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
shareholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
is finally judicially determined to constitute fraud, gross negligence or willful misconduct), or (c) in connection with any Registration
Statement of the Company providing for the resale by any Purchaser Party of the Shares issued, the Company will indemnify each Purchaser
Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i) any untrue or alleged
untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment
or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in
the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such untrue
statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by such Purchaser
Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or
any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought against any Purchaser
Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in
writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to
such Purchaser Party. Any Purchaser Party shall have the right to engage separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (x) the engagement
thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable period of time to assume
such defense and to engage counsel or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material
issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for
the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under
this Agreement (1) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not
be unreasonably withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable
to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party
in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments
of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or
others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.9&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Reservation
of Common Stock</U></FONT>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
Shares pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.10&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Listing
of Common Stock</U></FONT>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the
shares of Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply
to list or quote all of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market.
The Company further agrees, if the Company applies to have the shares of Common Stock traded on any other Trading Market, it will then
include in such application all of the Shares and will take such other action as is necessary to cause all of the Shares to be listed
or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue
the listing and trading of its shares of Common Stock on a Trading Market and will comply in all material respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules of the Trading Market. For so long as the Company maintains a listing
or quotation of the shares of Common Stock on a Trading Market, the Company agrees to maintain the eligibility of the shares of Common
Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.11&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Subsequent
Equity Sales</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;From
the date hereof until 60 days after the date on which a Registration Statement registering for resale all of the Shares is declared effective
by the Commission (such applicable period, the &ldquo;<U>Restricted Period</U>&rdquo;), neither the Company nor any Subsidiary shall (i)
issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents
or (ii) file any registration statement or any amendment or supplement thereto, in each case other than as contemplated pursuant to the
Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;During
the Restricted Period, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company
or any of its Subsidiaries of shares of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable
Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues or sells any debt
or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of
Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the
trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities,
or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of
the Company or the market for the shares of Common Stock or (ii) enters into, or effects a transaction under, any agreement, including,
but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price. Any Purchaser shall
be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right
to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;Notwithstanding
the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an
Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.12&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Equal
Treatment of Purchasers</U></FONT><U>.</U> No consideration (including any modification of any Transaction Document) shall be offered
or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the
Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase,
disposition or voting of Shares or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.13&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Certain
Transactions and Confidentiality</U></FONT>. Each Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant
to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&rsquo;s securities during
the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly
with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by
the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the
existence and terms of this transaction. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the
contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited by this Agreement from effecting any transactions in any securities of the Company in accordance with applicable securities
laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.14&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Capital
Changes</U></FONT>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward share split
or reclassification of the Common Stock without the prior written consent of the Purchasers, provided that no consent shall be required
in the event that the Company undertakes a reverse share split for purposes of maintaining the listing of the shares of Common Stock on
the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Form
D; Blue Sky Filings</U></FONT>. The Company agrees to timely file a Form D with respect to the offering of the Shares as required under
Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company
shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Shares for, sale to the Purchasers at the
Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States and shall provide evidence of such
actions promptly upon request of any Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.1&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Termination</U></FONT>.
This Agreement may be terminated by the Company or by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only, and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party hereto to sue for any breach by any other party (or parties) hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.2&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Fees
and Expenses</U></FONT>. Except as expressly set forth in the Transaction Documents to the contrary, each party hereto shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to
the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.3&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Entire
Agreement</U></FONT>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or
written, with respect to such matters, which such parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.4&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notices</U></FONT>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30
p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is
delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached
hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>)Trading
Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party
to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages
attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.5&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Amendments;
Waivers</U></FONT>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial
Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and
adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Shares and the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.6&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Headings</U></FONT>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.7&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Successors
and Assigns</U></FONT>. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect to the transferred
Shares, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.8&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>No
Third-Party Beneficiaries</U></FONT>. The Placement Agent shall be the third-party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the
benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.9&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Governing
Law</U></FONT>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party hereto agrees that all Proceedings concerning the interpretations, enforcement and defense of
the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each
party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If any party hereto shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition
to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.10&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Survival</U></FONT>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Shares for a period of five (5)
years from the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.11&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Execution</U></FONT>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party hereto and delivered to the other party hereto, it being understood
that the parties hereto need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or
by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature page
was an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.12&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Severability</U></FONT>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.13&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Rescission
and Withdrawal Right</U></FONT>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or
withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole
or in part without prejudice to its future actions and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.14&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Replacement
of Shares</U></FONT>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.15&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Remedies</U></FONT>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties hereto agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law
would be adequate. Each party hereto agrees that it shall not have a remedy of punitive or consequential damages against the other and
hereby waives any right or claim to punitive or consequential damages it may now have or may arise in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.16&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Payment
Set Aside</U></FONT>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.17&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U></FONT>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.18&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Liquidated
Damages</U></FONT><U>.</U> The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.19&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Saturdays,
Sundays, Holidays, etc</U></FONT><U>.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.20&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Construction</U></FONT>.
The parties hereto agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward share splits,
share dividends, share combinations and other similar transactions of the shares of Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.21&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>WAIVER
OF JURY TRIAL</U></FONT>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY HERETO AGAINST ANY OTHER PARTY HERETO,
THE PARTIES HERETO EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HEALTH IN TECH, INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">701 S. Colorado Avenue, Ste. 1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stuart, Florida 34994</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tim Johnson</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tim Johnson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK<BR>
SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGE TO SECURITIES PURCHASE
AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned has caused
this Securities Purchase Agreement to be duly executed by its authorized signatory as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Purchaser: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Signature of Authorized Signatory of Purchaser</I>: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email Address of Authorized Signatory <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Facsimile Number of Authorized Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea028345601ex10-2.htm
<DESCRIPTION>REGISTRATION RIGHTS AGREEMENT, DATED AS OF MARCH 25, 2026, BY AND AMONG HEALTH IN TECH, INC., CRAIG-HALLUM CAPITAL GROUP LLC AND THE HOLDERS PARTY THERETO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Registration Rights Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of March 25, 2026, between Health In Tech, Inc., a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), and each of the several purchasers signatory hereto (each such purchaser, a &ldquo;<U>Purchaser</U>&rdquo;
and, collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement is made pursuant
to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the &ldquo;<U>Purchase Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and each Purchaser
hereby agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1. <U>Definitions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Capitalized terms used
and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.</B>
As used in this Agreement, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Advice</U>&rdquo;
shall have the meaning set forth in Section 6(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effectiveness
Date</U>&rdquo; means, with respect to the Initial Registration Statement required to be filed hereunder, and except to the extent delayed
as a direct result of a government shut down, Commission closure or other regulatory delays outside the reasonable control of the Company
following the Company&rsquo;s use of its commercially reasonable efforts, a date no later than the 45<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>
calendar day following the date of the Filing Date of such Initial Registration Statement (or, in the event of a &ldquo;full review&rdquo;
by the Commission, a date no later than the 75<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT> calendar day following the initial filing
date of such Initial Registration Statement and with respect to any additional Registration Statements which may be required pursuant
to Section 2(c) or Section 3(c), a date no later than the 45<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT> calendar day following
the date on which an additional Registration Statement is required to be filed hereunder (or, in the event of a &ldquo;full review&rdquo;
by the Commission, a date no later than the 75<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT> calendar day following the date such
additional Registration Statement is required to be filed hereunder); <U>provided</U>, <U>however</U>, that in the event the Company is
notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further
review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which
the Company is so notified if such date precedes the dates otherwise required above, provided, further, that if any such Effectiveness
Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Event</U>&rdquo;
shall have the meaning set forth in Section 2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Event
Date</U>&rdquo; shall have the meaning set forth in Section 2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Filing
Date</U>&rdquo; means, with respect to the Initial Registration Statement required hereunder, a date no later than the 30th calendar day
after the date hereof, and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related
to the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Holder</U>&rdquo;
or &ldquo;<U>Holders</U>&rdquo; means the holder or holders, as the case may be, from time to time of Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Initial
Registration Statement</U>&rdquo; means the initial Registration Statement filed pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Losses</U>&rdquo;
shall have the meaning set forth in Section 5(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Plan of
Distribution</U>&rdquo; shall have the meaning set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously
omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission
pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of
any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus,
including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registrable
Securities</U>&rdquo; means, as of any date of determination, (a) all Shares and (b) any securities issued or then issuable upon any share
split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; <U>provided, however</U>, that
any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness
of any, or file another, Registration Statement hereunder with respect thereto) for so long as (x) a Registration Statement with respect
to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities
have been transferred, exchanged or disposed of by the Holder in accordance with such effective Registration Statement, (y) such Registrable
Securities have been previously sold in accordance with Rule 144, or (z) such Registrable Securities become eligible for resale without
volume or manner-of-sale restrictions and without the requirement for the Company to be in compliance with the current public information
requirement under Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer
Agent and the affected Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange of which,
or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company, as reasonably
determined by the Company, upon the advice of counsel to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 415</U>&rdquo;
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Selling
Shareholder Questionnaire</U>&rdquo; shall have the meaning set forth in Section 3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Guidance</U>&rdquo;
means (i) any publicly available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission
staff and (ii) the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
mean the shares of Common Stock issued or issuable to each Purchaser pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2. <U>Shelf Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) On or prior
to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the
Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous
basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible
to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on Form S-1 or another appropriate
form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by at least 85% in
interest of the Holders) substantially the &ldquo;<U>Plan of Distribution</U>&rdquo; attached hereto as <U>Annex A</U> and substantially
the &ldquo;<U>Selling Shareholder</U>&rdquo; section attached hereto as <U>Annex B</U>; <U>provided</U>, <U>however</U>, that no Holder
shall be required to be named as an &ldquo;underwriter&rdquo; without such Holder&rsquo;s express prior written consent. Subject to the
terms of this Agreement, the Company shall use its commercially reasonable efforts to cause a Registration Statement filed under this
Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as possible
after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such
Registration Statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such
Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions
pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under
Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to
the Transfer Agent and the affected Holders (the period commencing on the Effectiveness Date and ending on the later of the dates set
forth in clause (i) or (ii) of the preceding proviso, the &ldquo;<U>Effectiveness Period</U>&rdquo;). The Company shall telephonically
request effectiveness of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall promptly notify
the Holders via facsimile or by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically
confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company
shall, by 9:30 a.m. (New York City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus
with the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness
or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) Notwithstanding
the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities cannot,
as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company
agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration
Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission,
on Form S-3, Form S-1 or such other form available to register for resale the Registrable Securities as a secondary offering, subject
to the provisions of Section 2(d) with respect to any payment of liquidated damages and subject to the provisions of Section 2(e); <U>provided</U>,
<U>however</U>, that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission
for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance
and Disclosure Interpretation 612.09.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Notwithstanding
any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the Commission or
any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration
Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the
registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable
Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt; text-align: justify; text-indent: 24.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt; text-align: justify; text-indent: 24.65pt">i.&nbsp;First,
the Company shall reduce or eliminate any securities to be included other than Registrable Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt; text-align: justify; text-indent: 24.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt; text-align: justify; text-indent: 20.15pt">ii.&nbsp;Second,
the Company shall reduce Registrable Securities represented by Shares (applied, in the case that some Shares may be registered, to the
Holders on a pro rata basis based on the total number of unregistered Shares held by such Holders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt; text-align: justify; text-indent: 20.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event of a cutback hereunder,
the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to such Holder&rsquo;s
allotment. In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its
commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company
or to registrants of securities in general, one or more registration statements on Form S-3, Form S-1 or such other form available to
register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) If:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">i.&nbsp;the
Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration Statement without
affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall be deemed
to have not satisfied this clause (i)), or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">ii.&nbsp;the
Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated
by the Commission pursuant to the Securities Act, within five (5) Trading Days of the date that the Company is notified (orally or in
writing, whichever is earlier) by the Commission that such Registration Statement will not be &ldquo;reviewed&rdquo; or will not be subject
to further review, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">iii.&nbsp;prior
to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing
to comments made by the Commission in respect of such Registration Statement within ten (10) calendar days after the receipt of comments
by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective; provided,
however, that to the extent that the filing of an amendment to the Registration Statement under this clause (iii) would require updated
audited financial statements to be filed by amendment to the Registration Statement pursuant to the Securities Act in advance of the applicable
filing deadline for such audited financial statements under the Exchange Act, the applicable Event Date with respect thereto shall be
five (5) Trading Days after the applicable Exchange Act deadline; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">iv.&nbsp;a
Registration Statement registering for resale all of the Registrable Securities, subject to the cutback limitations set forth in Section
2(c) of this Agreement, is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">v.&nbsp;after
the effective date of a Registration Statement but prior to the end of the Effectiveness Period, such Registration Statement ceases for
any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are
otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than fifteen (15) consecutive
calendar days or more than an aggregate of twenty five (25) calendar days (which need not be consecutive calendar days) during any 12-month
period (any such failure or breach being referred to as an &ldquo;<U>Event</U>&rdquo;, and for purposes of clauses (i) and (iv), the date
on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose
of clause (iii) the date which such ten (10) or fifteen (15) calendar day period is exceeded, and for purpose of clause (v) the date on
which such fifteen (15) or twenty five (25) calendar day period, as applicable, is exceeded being referred to as &ldquo;<U>Event Date</U>&rdquo;),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">then, in addition
to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of
each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company
shall pay to each Holder an amount in cash, in newly issued shares of Common Stock, rounded down to the nearest whole share (at the Per
Share Purchase Price), at the sole option of the respective Purchaser, as partial liquidated damages and not as a penalty, equal to the
product of 2.0% multiplied by the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement; provided, however,
that (A) in no event shall the aggregate amount of liquidated damages payable by the Company to any Holder exceed 6% of the Subscription
Amount paid by such Holder pursuant to the Purchase Agreement, and (B) the Company shall not be liable for any liquidated damages pursuant
to this Section 2(d) or for any failure or delay in performance of any of its obligations contemplated by this Agreement to the extent
resulting from any event of force majeure, including, but not limited to, acts of God, acts of war or terrorism, natural disasters, pandemics,
government shutdowns, or Commission or other regulatory delays outside the reasonable control of the Company following the Company&rsquo;s
use of its commercially reasonable efforts; provided further, that, in no case shall the Company be required to issue any shares of Common
Stock in violation of the listing rules of the Nasdaq Stock Market LLC; and provided, further, that the Company shall not be required
to make any payments pursuant to this Section 2(d) with respect to any Registrable Securities the Company is unable to register due to
limits imposed by the Commission&rsquo;s interpretation of Rule 415 under the Securities Act as contemplated by Section 2(b). If the Company
fails to pay any partial liquidated damages pursuant to this Section in full within seven (7) days after the date payable, the Company
will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to
the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are
paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month
prior to the cure of an Event. Notwithstanding anything contained herein, no liquidated damages shall accrue or be payable with respect
to Holder if a delay in meeting any Filing Date deadline or Effective Date deadline is due in whole or in part to the actions, inactions
or directives (including under Section 3(a)) of any Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) If Form S-3
is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of
the Registrable Securities on Form S-1 or another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3
as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect
until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) Notwithstanding
anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate of a Holder as any
Underwriter without the prior written consent of such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">3. <U>Registration Procedures</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">In connection
with the Company&rsquo;s registration obligations hereunder, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Not less than
one (1) Trading Day prior to the filing of the Initial Registration Statement and not less than three (3) Trading Days prior to the filing
of each additional Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment
or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference), the Company
shall (i) furnish to each Holder copies of all such documents proposed to be filed, which documents (other than those incorporated or
deemed to be incorporated by reference) will be subject to the review of such Holders, and (ii) cause its officers and directors, counsel
and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective
counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file a Registration
Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities
shall reasonably object in good faith, provided that, the Company is notified of such objection in writing no later than three (3) Trading
Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so
furnished copies of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed
questionnaire in the form attached to this Agreement as <U>Annex B </U>(a &ldquo;<U>Selling Shareholder Questionnaire</U>&rdquo;) on a
date that is not less than three (3) Trading Days prior to the Filing Date or by the end of the fourth (4<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>)
Trading Day following the date on which such Holder receives draft materials in accordance with this Section. In addition to the Selling
Shareholder Questionnaire, each Holder shall furnish such other information as shall be reasonably required to effect the registration
of such Registrable Securities, and shall execute such documents in connection with such registration as the Company may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">i.&nbsp;Prepare
and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used
in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities
for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for
resale under the Securities Act all of the Registrable Securities,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">ii.&nbsp;cause
the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and,
as so supplemented or amended, to be filed pursuant to Rule 424,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">iii.&nbsp;respond
as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment
thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission
relating to a Registration Statement (provided that, the Company shall excise any information contained therein which would constitute
material non-public information regarding the Company or any of its Subsidiaries), and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">iv.&nbsp;comply
in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of
all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this
Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in
such Prospectus as so supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) If during the
Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered
in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing
Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) Notify the Holders
of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction
to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case
of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such notice in
writing no later than one (1) Trading Day following the day</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">i.&nbsp;(A)
when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when
the Commission notifies the Company whether there will be a &ldquo;review&rdquo; of such Registration Statement and whenever the Commission
comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment,
when the same has become effective,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">ii.&nbsp;of
any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement
or Prospectus or for additional information,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">iii.&nbsp;of
the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of
a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">iv.&nbsp;of
the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of
any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">v.&nbsp;of
the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for
inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated
therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents
so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 13.5pt">vi.&nbsp;of
the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material
and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration
Statement or Prospectus; <U>provided</U>, <U>however</U>, that in no event shall any such notice contain any information which would constitute
material, non-public information regarding the Company or any of its Subsidiaries (unless such information is legally required to be included
in such notice).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) Use its commercially
reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness
of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities
for sale in any jurisdiction, at the earliest practicable moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) Furnish to each
Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial
statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such
Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly
after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or successor
thereto) need not be furnished in physical form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) Subject to the
terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of
the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment
or supplement thereto, except after the giving of any notice pursuant to Section 3(d). The Company may require any Holder or any of its
affiliates who is deemed to be an underwriter, in the Company&rsquo;s reasonable judgment, to provide such additional information as may
be necessary to comply with the Securities Act or SEC Guidance, and may restrict or prohibit any method of distribution not permitted
by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) Prior to any
resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling
Holders in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable
Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder
reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness
Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable
Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally to do business
in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not
then so subject or file a general consent to service of process in any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) If requested
by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates, or book entry notification
as applicable, representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates
or book entry notification shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable
such Registrable Securities to be in such denominations and registered in such names as any such Holder may request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) Upon the occurrence
of any event contemplated by Section 3(d), if required to do so, as promptly as reasonably possible under the circumstances taking into
account the Company&rsquo;s good faith assessment of any adverse consequences to the Company and its shareholders of the premature disclosure
of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to
the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document
so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section
3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
so suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may
be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability
of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section
2(d), for a period not to exceed 90 calendar days (which need not be consecutive days) in any 12-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k) Otherwise use
commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and the
Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or
amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at any
time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the
Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions
as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) Use its commercially
reasonable efforts to maintain eligibility for use of Form S-3 or Form S-1 (or any successor forms thereto) for the registration of the
resale of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m) The Company
may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially
owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the
shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable
Securities solely because any Holder fails to furnish such information within three (3) Trading Days of the Company&rsquo;s request, any
liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely
because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company. The Company shall
have no liability or obligation to any Holder with respect to any delay or failure to register Registrable Securities or maintain effectiveness
of a Registration Statement resulting from such Holder&rsquo;s failure to timely provide the information requested by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4. <U>Registration Expenses</U>.
All fees and expenses incident to the performance of or compliance with this Agreement by the Company shall be borne by the Company whether
or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence
shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Company&rsquo;s
counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings
required to be made with any Trading Market on which the shares of Common Stock are then listed for trading, and (C) in compliance with
applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements
of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses
(including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery
expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such
insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions
contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection
with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of
its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred
in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company
be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents,
any legal fees or other costs of the Holders. Notwithstanding the foregoing, if any Holder requests amendments or supplemental filings
to a Registration Statement or Prospectus that are not otherwise required by applicable law or Commission guidance and that benefit only
such Holder, based on a commercially reasonable determination by the Company upon the advice of counsel, such Holder shall reimburse the
Company for the reasonable and documented incremental expenses incurred in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5. <U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Indemnification
by the Company</U>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the
officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a
result of a pledge or any failure to perform under a margin call of shares of Common Stock), investment advisors and employees (and any
other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title)
of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act) and the officers, directors, members, shareholders, partners, agents and employees (and any other Persons with a functionally
equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person,
to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;<U>Losses</U>&rdquo;), as incurred, arising out
of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus
or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to
any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the
case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such
untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder
expressly for use therein, or to the extent that such information relates to such Holder or such Holder&rsquo;s proposed method of distribution
of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement,
such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose)
or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated,
defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective
or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). The
Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with
the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any
of the Holders in accordance with Section 6(f). The Company shall not be liable under this Section 5(a) for any Losses to the extent arising
out of or based upon the gross negligence, willful misconduct, or fraud of an Indemnified Party, or resulting from a final, non-appealable
judgment of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Indemnification
by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents
and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, agents or employees of such controlling Persons (and any other Persons with a functionally equivalent
role of a Person holding such titles, notwithstanding a lack of such title or any other title), to the fullest extent permitted by applicable
law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement
of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information
so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii)
to the extent, but only to the extent, that such information relates to such Holder&rsquo;s information provided in the Selling Shareholder
Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such
Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this purpose),
such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than
the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and
the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such
Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Conduct of
Indemnification Proceedings</U>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an
&ldquo;<U>Indemnified Party</U>&rdquo;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &ldquo;<U>Indemnifying
Party</U>&rdquo;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment
of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense
thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations
or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent
jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced
the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">An Indemnified Party
shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing
to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ
counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including
any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably
believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying
Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at
the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable
fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall
not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably
withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of
any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release
of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Subject to the terms
of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred
in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid
to the Indemnified Party, as incurred, within ten (10) Trading Days of written notice thereof to the Indemnifying Party, provided that
the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions
for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal
or further review) not to be entitled to indemnification hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Contribution</U>.
If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party
harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such
proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions,
statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such
Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by,
or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party
as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&rsquo;
or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified
for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The parties hereto
agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or
by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding
paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount
of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any
damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission)
received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The indemnity and
contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified
Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">6. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) Remedies. In
the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company,
as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of
damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder agrees that
monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions
of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall
not assert or shall waive the defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) No Piggyback
on Registrations; Prohibition on Filing Other Registration Statements. Neither the Company nor any of its security holders (other than
the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable
Securities. The Company shall not file any other registration statements, other than with respect to an Exempt Issuance (as defined in
the Purchase Agreement), until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective
by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing amendments to registration statements filed
prior to the date of this Agreement so long as no new securities are registered on any such existing registration statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Discontinued
Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence
of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition of such Registrable
Securities under a Registration Statement until it is advised in writing (the &ldquo;Advice&rdquo;) by the Company that the use of the
applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its best efforts to ensure that
the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges that any periods during which
the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section
2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) Amendments and
Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and
waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company
and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes any Registrable
Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification or waiver disproportionately
and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall
be required. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in
compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro
rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such
Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter
that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other
Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided,
however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of
the first sentence of this Section 6(d). No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification
of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement who continue
to hold any of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) Notices. Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in
the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) Successors and
Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties
and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder without
the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their respective
rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement; provided, however, that (i)
except for assignments to affiliates or as otherwise set forth in the Purchase Agreement, no such assignment shall be effective without
the prior written consent of the Company (not to be unreasonably withheld or delayed), and (ii) any such assignee must agree in writing
to be bound by all terms and conditions of this Agreement as if an original Holder hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) No Inconsistent
Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries,
on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing
the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Except as set forth on Schedule
6(i), neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with
respect to any of its securities to any Person that have not been satisfied in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) Execution and
Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature
page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) Governing Law.
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) Cumulative Remedies.
The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k) Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) Headings. The
headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m) Independent
Nature of Holders&rsquo; Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the obligations
of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder
hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder
pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind
of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect to
such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders
are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions.
Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement,
and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of
a single agreement with respect to the obligations of the Company contained was solely in the control of the Company, not the action or
decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by
any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a Holder,
solely, and not between the Company and the Holders collectively and not between and among Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n) Termination.
This Agreement shall be effective as of the Closing, and if the Closing has not occurred on or prior to fifth (5th) Trading Day following
the date of the Purchase Agreement, unless otherwise mutually agreed, then this Agreement shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o) No Other Registration
Rights. Except as expressly provided herein, no Holder shall have any right to require the Company to include any Registrable Securities
in any registration statement filed by the Company for its own account or for the account of any other holder of securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HEALTH IN TECH, INC. </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tim Johnson</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tim Johnson</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">[SIGNATURE
PAGE OF HOLDERS TO Follow]</FONT><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">[SIGNATURE
PAGE OF HOLDERS TO RRA]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Holder: _________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Holder</I>:
__________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: __________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Annex A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each selling shareholder (each,
a &ldquo;<U>Selling Shareholder</U>&rdquo; and, collectively, the &ldquo;<U>Selling Shareholders</U>&rdquo;) of the securities and any
of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on
the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private
transactions. These sales may be at fixed or negotiated prices. A Selling Shareholder may use any one or more of the following methods
when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">privately negotiated transactions;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">in transactions through broker-dealers that agree with the Selling Shareholders to sell a specified number of such securities at a stipulated price per security;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">a combination of any such methods of sale; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any other method permitted pursuant to applicable law.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholders may
also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by
the Selling Shareholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Shareholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in
compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholders and
any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each Selling Shareholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is required to
pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify
the Selling Shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. The
Company shall not be responsible for any of the Selling Shareholders&rsquo; selling costs incurred pursuant to any available method provided
hereunder for selling securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to keep this prospectus
effective until the earlier of (i) the date on which the securities may be resold by the Selling Shareholders without registration and
without regard to any volume or manner-of-sale limitations by reason of Rule 144 under the Securities Act, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule
of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied
with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market
making activities with respect to the shares of common stock for the applicable restricted period, as defined in Regulation M, prior to
the commencement of the distribution. In addition, the Selling Shareholders will be subject to applicable provisions of the Exchange Act
and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the shares of common
stock by the Selling Shareholders or any other person. We will make copies of this prospectus available to the Selling Shareholders and
have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by
compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Annex B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELLING SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
being offered by the selling shareholders are those previously issued to the selling shareholders. For additional information regarding
the issuances of those shares of common stock, see &ldquo;Private Placement of Shares of Common Stock&rdquo; above. We are registering
the shares of common stock in order to permit the selling shareholders to offer the shares for resale from time to time. Except for the
ownership of the shares of common stock, the selling shareholders have not had any material relationship with us within the past three
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the
selling shareholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling shareholders.
The second column lists the number of shares of common stock beneficially owned by each selling shareholder, based on its ownership of
the shares of common stock, as of ________, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The third column lists the
shares of common stock being offered by this prospectus by the selling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the terms
of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the number of shares
of common stock issued to the selling shareholders in the &ldquo;Private Placement of Shares of Common Stock&rdquo; described above. The
fourth column assumes the sale of all of the shares offered by the selling shareholders pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling shareholders may
sell all, some or none of their shares in this offering. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Name of Selling Shareholder</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><B>Number of Shares of Common Stock Owned Prior to Offering</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><B>Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><B>Number of Shares of Common Stock Owned After Offering</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B><U>Annex C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>HEALTH
IN TECH, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Selling Shareholder Notice and Questionnaire</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned beneficial
owner of shares of common stock (the &ldquo;<U>Registrable Securities</U>&rdquo;) of Health In Tech, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
understands that the Company has filed or intends to file with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
a registration statement (the &ldquo;<U>Registration Statement</U>&rdquo;) for the registration and resale under Rule 415 of the Securities
Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of the Registrable Securities, in accordance with the terms of the
Registration Rights Agreement (the &ldquo;<U>Registration Rights Agreement</U>&rdquo;) to which this document is annexed. A copy of the
Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise
defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal consequences
arise from being named as a selling shareholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial
owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or
not being named as a selling shareholder in the Registration Statement and the related prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned beneficial
owner (the &ldquo;<U>Selling Shareholder</U>&rdquo;) of Registrable Securities hereby elects to include the Registrable Securities owned
by it in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby provides the following
information to the Company and represents and warrants that such information is accurate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>QUESTIONNAIRE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD><B>Name.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Full Legal Name of Selling Shareholder</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities
are held:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone
or with others has power to vote or dispose of the securities covered by this Questionnaire):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>2. Address for Notices to Selling Shareholder:</B></P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; width: 0.5in"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 0.5in; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 100%">Telephone:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">E-Mail:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Contact Person:<U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>3. Broker-Dealer Status:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Are you a broker-dealer?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If &ldquo;yes&rdquo; to Section 3(a), did you receive your Registrable Securities as compensation for
investment banking services to the Company?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">Note:</TD><TD STYLE="text-align: justify">If &ldquo;no&rdquo; to Section 3(b), the Commission&rsquo;s
staff has indicated that you should be identified as an underwriter in the Registration Statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Are you an affiliate of a broker-dealer?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities
in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements
or understandings, directly or indirectly, with any person to distribute the Registrable Securities?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;Yes &#9744; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">Note:</TD><TD STYLE="text-align: justify">If &ldquo;no&rdquo; to Section 3(d), the Commission&rsquo;s
staff has indicated that you should be identified as an underwriter in the Registration Statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>4. Beneficial Ownership of Securities
of the Company Owned by the Selling Shareholder.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Except as set forth below in this
Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable
pursuant to the Purchase Agreement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Type and Amount of other securities beneficially owned by the Selling Shareholder:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1.5pt; width: 0.5in"></TD><TD STYLE="padding-bottom: 1.5pt; width: 0.5in; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>5. Relationships with the Company:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Except as set forth below, neither
the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities
of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or
affiliates) during the past three years.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">State any exceptions here:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1.5pt; width: 0.5in"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 0.5in; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledge
that the Securities Act and the rules and regulation promulgated thereunder may require the undersigned to promptly notify the Company
of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time as
long as the undersigned holds Registrable Securities (as defined in the Registration Rights Agreement). In the absence of any such notification,
the Company shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, the undersigned
consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information
in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such
information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related
prospectus and any amendments or supplements thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF the undersigned,
by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized
agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp; <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial Owner: <U>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 3%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 32%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND
EXECUTED NOTICE AND QUESTIONNAIRE TO BOTH:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tim Johnson, Chief Executive Officer of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: tjohnson@healthintech.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><U>and</U></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alexandria E. Kane, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: akane@loeb.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ea028345601ex10-3.htm
<DESCRIPTION>PLACEMENT AGENCY AGREEMENT, DATED AS OF MARCH 25, 2026, 2025, BY AND BETWEEN HEALTH IN TECH, INC. AND CRAIG-HALLUM CAPITAL GROUP LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt 0">March 25, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Health In Tech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">701 S. Colorado Ave, Suite 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stuart, FL 34994</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attention: Mr. Timothy Johnson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Johnson:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter (the &ldquo;<B>Agreement</B>&rdquo;)
constitutes the agreement between Craig-Hallum Capital Group LLC (the &ldquo;<B>Placement Agent</B>&rdquo;) and Health in Tech, Inc.,
a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), that the Placement Agent shall serve as the exclusive placement agent for the
Company, on a &ldquo;reasonable best efforts&rdquo; basis, in connection with the proposed placement (the &ldquo;<B>Placement</B>&rdquo;)
of shares of Class A common stock, par value $0.001 per share, of the Company (the &ldquo;<B>Securities</B>&rdquo;). The Securities shall
be offered and sold pursuant to an exemption from registration under Section&#8239;4(a)(2)&#8239;of the Securities Act and Rule&#8239;506
promulgated thereunder. The terms of the Placement shall be mutually agreed upon by the Company and each purchaser of the Securities (each,
a &ldquo;<B>Purchaser</B>&rdquo; and collectively, the &ldquo;<B>Purchasers</B>&rdquo;), and nothing herein constitutes that the Placement
Agent would have the power or authority to bind the Company or any Purchaser, or an obligation for the Company to issue any Securities
or complete the Placement. The Company expressly acknowledges and agrees that the Placement Agent&rsquo;s obligations hereunder are on
a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by the Placement Agent
to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of the
Placement Agent with respect to securing any other financing on behalf of the Company. The Placement Agent may retain other brokers or
dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement. Certain affiliates of the Placement Agent
may participate in the Placement by purchasing some of the Securities. The sale of Securities to each Purchaser will be evidenced by a
securities purchase agreement (the &ldquo;<B>Purchase Agreement</B>&rdquo;) between the Company and such Purchaser(s), in a form reasonably
acceptable to the Company and such Purchaser(s). Capitalized terms that are not otherwise defined herein have the meanings given to such
terms in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company will be available to answer inquiries
from any prospective Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 1</U>. <U>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. <U>Representations of the
Company</U>. With respect to the Securities, each of the representations and warranties (together with any related disclosure schedules
thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement, is hereby incorporated
herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement and as of the Closing
Date, hereby made to, and in favor of, the Placement Agent. In addition to the foregoing, the Company represents and warrants that there
are no affiliations with any member firm of the Financial Industry Regulatory Authority, Inc. (&rdquo;<B>FINRA</B>&rdquo;) participating
in the Placement among the Company&rsquo;s officers, directors or, to the knowledge of the Company, any five percent (5.0%) or greater
securityholder of the Company, except as set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. <U>Covenants of the Company</U>.
The Company covenants and agrees to continue to retain (i) a firm of independent PCAOB registered public accountants for a period of at
least five (5) years after the Closing Date and (ii) a competent transfer agent with respect to the Securities for a period of five (5)
years after the Closing Date. In addition, from the date hereof, the Company agrees that the Placement Agent shall be a third-party beneficiary
of Section 4.11 of the Purchase Agreement, and that the Placement Agent shall have the ability to enforce the restrictions contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 2</U>. <U>REPRESENTATIONS
OF THE PLACEMENT AGENT</U>. The Placement Agent represents and warrants that it (i) is a member in good standing of FINRA, (ii) is registered
as a broker/dealer under the Exchange Act, (iii) is licensed as a broker/dealer under the laws of the United States of America, applicable
to the offers and sales of the Securities by the Placement Agent, (iv) is validly existing under the laws of its place of formation, and
(v) has full power and authority to enter into and perform its obligations under this Agreement. The Placement Agent will immediately
notify the Company in writing of any change in its status with respect to subsections (i) through (v) above. The Placement Agent covenants
that it will use its reasonable best efforts to conduct the Placement hereunder in compliance with the provisions of this Agreement and
the requirements of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Placement Agency Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 3</U>. <U>COMPENSATION
AND EXPENSES</U>. In consideration of the services to be provided for hereunder, the Company shall pay to the Placement Agent and/or its
respective designees a cash fee of 6.0% of all gross proceeds received from the sale of the Securities, plus an additional 1.0% of the
portion of gross proceeds received from the sale of the Securities to Purchasers that are considered institutional investors in accordance
with FINRA Rule 4512(c) (the &ldquo;<B>Cash Fee</B>&rdquo;). The Company shall also pay (i) all reasonable and documented out-of-pocket
accountable legal fees of counsel of the Placement Agent, (ii) reasonable and documented travel expenses of the Placement Agent related
to the Placement and (iii) reasonable and documented out-of-pocket accountable third-party expenses incurred by the Placement Agent in
connection with the Placement (such expenses in the preceding clauses (i)-(iii), the &ldquo;<B>Reimbursable Expenses</B>&rdquo;). Excluding
expenses related to blue sky compliance and FINRA filings, such total Reimbursable Expenses for an Offering shall not exceed $125,000
without the Company&rsquo;s prior written approval (which shall not be unreasonably withheld, conditioned or delayed). The Placement Agent
reserves the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event that a determination
shall be made by FINRA to the effect that the Placement Agent&rsquo;s aggregate compensation is in excess of FINRA Rules or that the terms
thereof require adjustment. The Cash Fee and the Reimbursable Expenses shall be paid to the Placement Agent and/or its respective designees
(which may be its counsel, as it relates to the Reimbursable Expenses) promptly on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 4</U>. <U>INDEMNIFICATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. To the extent permitted by
law, with respect to the Securities, the Company will indemnify the Placement Agent and its affiliates, stockholders, directors, officers,
employees, members, counsel and controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act) against all losses, claims, damages, expenses and liabilities, as the same are incurred (including the reasonable fees and expenses
of counsel), relating to or arising out of its activities hereunder, its status, title or role as Placement Agent or pursuant to this
Agreement, except to the extent that any losses, claims, damages, expenses or liabilities (or actions in respect thereof) are found in
a final judgment (not subject to appeal) by a court of law to have resulted primarily and directly from the Placement Agent&rsquo;s fraud,
willful misconduct or gross negligence in performing the services described herein. Notwithstanding anything set forth herein to the contrary,
the Company agrees to indemnify Placement Agent and its counsel, Faegre Drinker Biddle and Reath LLP, to the fullest extent set forth
in this Section 4, against any and all claims asserted by any or person or entity alleging that the Placement Agent was not permitted
or entitled to act as Placement Agent herein, or that the Company was not permitted to hire or retain Placement Agent herein, including
but not limited to any claims arising out of any purported right of first refusal another person or entity claims to have to act as a
placement agent or any similar role with respect to the Company or its securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. Promptly after receipt by
the Placement Agent of notice of any claim or the commencement of any action or proceeding with respect to which the Placement Agent is
entitled to indemnity hereunder, the Placement Agent will notify the Company in writing of such claim or of the commencement of such action
or proceeding, but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder, except and
only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company so elects
or is requested by the Placement Agent, the Company will assume the defense of such action or proceeding and will employ counsel reasonably
satisfactory to the Placement Agent and will pay the fees and expenses of such counsel. Notwithstanding the preceding sentence, the Placement
Agent will be entitled to engage counsel separate from counsel for the Company and from any other party in such action if counsel for
the Placement Agent reasonably determines that it would be inappropriate under the applicable rules of professional responsibility for
the same counsel to represent both the Company and the Placement Agent. In such event, the reasonable fees and disbursements of no more
than one (1) such separate counsel will be paid by the Company, in addition to fees of local counsel. The Company will have the right
to settle the claim or proceeding provided that the Company will not settle any such claim, action or proceeding without the prior written
consent of the Placement Agent, which will not be unreasonably withheld. The Company shall not be liable for any settlement of any action
effected without its written consent, which will not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. The Company agrees to notify
the Placement Agent promptly of the assertion against it or any other person of any claim or the commencement of any action or proceeding
relating to a transaction contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D. If for any reason the foregoing
indemnity is unavailable to the Placement Agent or insufficient to hold the Placement Agent harmless, then the Company shall contribute
to the amount paid or payable by the Placement Agent as a result of such losses, claims, damages or liabilities in such proportion as
is appropriate to reflect not only the relative benefits received by the Company on the one hand and the Placement Agent on the other,
but also the relative fault of the Company on the one hand and the Placement Agent on the other that resulted in such losses, claims,
damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses,
claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and expenses incurred in defending
any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, the Placement Agent&rsquo;s share of the liability
hereunder shall not be in excess of the amount of fees actually received, or to be received, by the Placement Agent under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. These indemnification provisions
shall remain in full force and effect whether or not the transaction contemplated by this Agreement is completed and shall survive the
termination of this Agreement, and shall be in addition to any liability that the Company might otherwise have to any indemnified party
under this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 5</U>. <U>ENGAGEMENT
TERM</U>. The Placement Agent&rsquo;s engagement hereunder will commence on the date hereof and continue through the Closing Date. The
date of termination of this Agreement is referred to herein as the &ldquo;<B>Termination Date</B>.&rdquo; In the event, however, in the
course of the Placement Agent&rsquo;s performance of due diligence it deems it necessary to terminate the engagement, the Placement Agent
may do so prior to the Termination Date. The Company may elect to terminate the engagement hereunder for any reason prior to the Termination
Date but will remain responsible for fees and expenses pursuant to Section 3 hereof and fees and expenses with respect to the Securities,
if sold in the Placement. Notwithstanding anything to the contrary contained herein, the provisions concerning the Company&rsquo;s obligation
to pay any fees or expenses actually earned pursuant to Section 3 hereof and the provisions concerning confidentiality, indemnification
and contribution contained herein will survive any expiration or termination of this Agreement. If this Agreement is terminated prior
to the completion of the Placement, all fees or expenses due to the Placement Agent shall be paid by the Company to the Placement Agent
on or before the Termination Date (in the event such fees or expenses are earned or owed as of the Termination Date). The Placement Agent
agrees not to use any confidential information concerning the Company provided to the Placement Agent by the Company for any purposes
other than those contemplated under this Agreement. For the avoidance of doubt, and notwithstanding the foregoing, the Company and the
Placement Agent agree that this Section 5 shall in no way alter the terms of the letter agreement by and between the Placement Agent and
the Company dated January 30, 2026, which the parties acknowledge and agree shall not be superseded by this Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 6</U>. <U>PLACEMENT
AGENT INFORMATION</U>. The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement
is for the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the Company
will not disclose or otherwise refer to the advice or information in any manner without the Placement Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 7</U>. <U>NO FIDUCIARY
RELATIONSHIP</U>. This Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not
a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that
the Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity
holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement Agent hereunder,
all of which are hereby expressly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 8</U>. <U>CLOSING</U>.
The obligations of the Placement Agent, and the closing of the sale of the Securities hereunder are subject to the accuracy, when made
and on the Closing Date, of the representations and warranties on the part of the Company contained herein and in the Purchase Agreement,
to the performance by the Company of its obligations hereunder and in the Purchase Agreement, and to each of the following additional
terms and conditions, except as otherwise disclosed to and acknowledged and waived by the Placement Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. All corporate proceedings
and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Securities,
and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the Securities shall be
reasonably satisfactory in all material respects to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. The Placement Agent shall
have received from outside counsel to the Company such counsel&rsquo;s written opinion with respect to the Securities, addressed to the
Placement Agent and dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. The Placement Agent shall
have received customary certificates of the Company&rsquo;s executive officers, as to the accuracy of the representations and warranties
contained in the Purchase Agreement, and a certificate of the Company&rsquo;s secretary certifying that each of the Company&rsquo;s charter
documents are true and complete, have not been modified and are in full force and effect; (ii) that the resolutions of the Company&rsquo;s
Board of Directors relating to the Placement are in full force and effect and have not been modified; and (iii) as to the incumbency of
the officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D. The Company shall have filed
a Listing of Additional Shares notification form with The Nasdaq Stock Market LLC (the &ldquo;Nasdaq&rdquo;) and shall not have received
any objection to such form from Nasdaq. The Company shall have taken no action designed to, or likely to have the effect of, delisting
or suspending from trading the Securities from Nasdaq or other applicable U.S. national exchange, nor has the Company received any information
suggesting that Nasdaq or other applicable U.S. national exchange is contemplating terminating such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. No action shall have been
taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would,
as of the Closing Date, prevent the issuance or sale of the Securities or materially and adversely affect or potentially materially and
adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any federal
or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance or sale of the
Securities or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F. The Company shall have entered
into a Purchase Agreement with the Purchasers of the Securities and such agreement shall be in full force and effect and shall contain
representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">G. The Company has furnished
to the Placement Agent a letter agreement in the form attached hereto as Exhibit A (the &ldquo;<B>Lock-up Agreement</B>&rdquo;) from each
executive officer and director of the Company. If any additional persons shall become directors or officers of the Company prior to the
end of the Lock-Up Period (as defined in the Lock-Up Agreement), the Company shall cause each such person, prior to or contemporaneously
with their appointment or election as a director or officer of the Company, to execute and deliver to the Placement Agent a Lock-up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">H. On the date of this Agreement
and on the Closing Date, as the case may be, MaloneBailey LLP shall have furnished to the Placement Agent, at the request of the Company,
letters, dated the respective dates of delivery thereof and addressed to the Placement Agent, in form and substance reasonably satisfactory
to the Placement Agent, containing statements and information of the type customarily included in accountants&rsquo; &ldquo;comfort letters&rdquo;
to underwriters with respect to the financial statements and certain financial information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section 8 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agent hereunder
may be cancelled by the Placement Agent at, or at any time prior to, the Closing Date. Notice of such cancellation shall be given to the
Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 9</U>. <U>GOVERNING
LAW</U>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements
made and to be performed entirely in such State, without regard to its conflict of laws principles. This Agreement may not be assigned
by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of
the parties hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising
under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought
into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this
Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid
courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either
party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorney&rsquo;s fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 10</U>. <U>ENTIRE
AGREEMENT/MISCELLANEOUS</U>. This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes
all prior agreements and understandings, relating to the subject matter hereof. If any provision of this Agreement is determined to be
invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision
of this Agreement, which will remain in full force and effect. This Agreement may not be amended or otherwise modified or waived except
by an instrument in writing signed by both the Placement Agent and the Company. The representations, warranties, agreements and covenants
contained herein shall survive the Closing Date of the Placement and delivery of the Securities. This Agreement may be executed in two
or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when
counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the
same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as
if such facsimile or .pdf signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 11</U>. <U>NOTICES</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the email address
specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day
after the date of transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on
a day that is not a business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following
the date of mailing, if sent by a U.S. internationally recognized air courier service, or (d) upon actual receipt by the party to whom
such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 12</U>. <FONT STYLE="text-transform: uppercase"><U>PRESS
ANNOUNCEMENTS</U></FONT>. The Company agrees that the Placement Agent shall, on and after the Closing Date, have the right to reference
the Placement and the Placement Agent&rsquo;s role in connection therewith in the Placement Agent&rsquo;s marketing materials and on its
website and to place advertisements in financial and other newspapers and journals, in each case at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The remainder of this page has been intentionally
left blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please confirm that the foregoing
correctly sets forth our agreement by signing and returning to the Placement Agent the enclosed copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>CRAIG-HALLUM CAPITAL GROUP LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Rick Hartfiel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Head of Investment Banking</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for notice:</U></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">323 North Washington Ave., Suite 300</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Minneapolis, Minnesota 55401</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Rick Hartfiel</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: rick.hartfiel@craig-hallum.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accepted and Agreed to as of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the date first written above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>HEALTH IN TECH, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="font-size: 10pt">Timothy Johnson</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Address for notice</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">701 S. Colorado Ave, Suite 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stuart, FL 34994</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Tim Johnson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: tjohnson@healthintech.com<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Placement Agency Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORM OF LOCK-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[&#9679;], 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Craig-Hallum Capital Group LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">323 North Washington Ave., Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Minneapolis, Minnesota 55401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">Re:</TD>
    <TD STYLE="font-size: 10pt">Health In Tech, Inc. &mdash; PIPE Offering</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned understands that you, as placement agent (the &ldquo;Agent&rdquo;),
propose to enter into a placement agency agreement (the &ldquo;Placement Agency Agreement&rdquo;) with Health In Tech, Inc., a Nevada
corporation (the &ldquo;Company&rdquo;), related to the placement (the &ldquo;Offering&rdquo;) by the Company, of Series A common stock,
par value $0.001 per share (the &ldquo;Common Stock&rdquo;), of the Company (the &ldquo;Securities&rdquo;). Capitalized terms used herein
and not otherwise defined shall have the meanings set forth in the Placement Agency Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In consideration of the Agent&rsquo;s agreement to enter into the Placement
Agency Agreement in connection with the Offering, and for other good and valuable consideration receipt of which is hereby acknowledged,
the undersigned hereby agrees that, without the prior written consent of the Agent, the undersigned will not, and will not cause any direct
or indirect affiliate to, during the period beginning on the date hereof and ending at the close of business 60 days after the effectiveness
of the resale registration statement for the Securities (the &ldquo;Restricted Period&rdquo;), (1) offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend,
or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially
owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may
be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, the &ldquo;Lock-Up Securities&rdquo;), (2)
enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of
ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of
Lock-Up Securities, in cash or otherwise, (3) make any demand for or exercise any right with respect to the registration of any Lock-Up
Securities, or (4) publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing
precludes the undersigned from engaging during the Restricted Period in any hedging or other transactions or arrangements (including,
without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward,
swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably
be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic
consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement
(or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise. The undersigned further
confirms that it has furnished the Agent with the details of any transaction the undersigned, or any of its affiliates, is a party to
as of the date hereof, which transaction would have been restricted by this Letter Agreement (the &ldquo;Letter Agreement&rdquo;) if it
had been entered into by the undersigned during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding the foregoing, the undersigned may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) transfer or dispose of the undersigned&rsquo;s Lock-Up Securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) as a bona fide gift or gifts, or for bona fide estate planning
purposes,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii) by will or intestacy,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) to any (A) immediate family of the undersigned or (B) trust for
the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor
or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &ldquo;immediate family&rdquo;
shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) to a corporation, partnership, limited liability company, trust
or other entity of which the undersigned and/or the immediate family of the undersigned are the legal and beneficial owner of all the
outstanding equity securities or similar interests,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(v) to a nominee or custodian of a person or entity to whom a disposition
or transfer would be permissible under clauses (i) through (iv) above,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(vi) if the undersigned is a corporation, partnership, limited liability
company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity
that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;))
of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control
with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership,
to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution
to members, partners, shareholders or other equityholders of the undersigned,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(vii) by operation of law, such as pursuant to a qualified domestic
order, divorce settlement, divorce decree or separation agreement, or related court order,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(viii) to the Company from an employee of the Company upon death, disability
or termination of employment, in each case, of such employee,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ix) as part of a sale of the undersigned&rsquo;s Lock-Up Securities
acquired in open market transactions after the completion of the Offering,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(x) to the Company in connection with the vesting, settlement, or exercise
of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &ldquo;net&rdquo;
or &ldquo;cashless&rdquo; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the
vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common
Stock received upon such exercise, vesting or settlement (other than such shares as are transferred or surrendered to the Company in connection
with such vesting, settlement or exercise event) shall be subject to the terms of this Letter Agreement, and provided further that any
such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted
under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the reports, schedules, forms,
statements and other documents required to be filed by the Company under the&nbsp;Securities
Act&nbsp;and&nbsp;the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the &ldquo;Exchange
Act&rdquo;), including pursuant to Section 13(a) or 15(d) thereof (the &ldquo;SEC Documents&rdquo;),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(xi) pursuant to a bona fide third-party tender offer, merger, consolidation
or other similar transaction that is approved by the board of directors of the Company and made to all holders of the Company&rsquo;s
capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, &ldquo;Change of Control&rdquo; shall
mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related
transactions, to a person or group of affiliated persons (other than the Agent pursuant to the Offering), of shares of capital stock if,
after such transfer, such person or group of affiliated persons would hold more than 75% of the outstanding voting securities of the Company
(or the surviving entity)); provided that in the event that such tender offer, merger, consolidation or other similar transaction is not
completed, the undersigned&rsquo;s Lock-Up Securities shall remain subject to the provisions of this Letter Agreement, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(xii) to a charity or educational institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>provided</U> that (A) in the case of any transfer or distribution
pursuant to clauses (a)(i), (ii), (iii), (iv), (v), (vi) and (xii), such transfer shall not involve a disposition for value, (B) in the
case of any transfer or distribution pursuant to clauses (a)(i), (ii), (iii), (iv), (v), (vi), (vii) and xii each donee, devisee, transferee
or distributee shall execute and deliver to the Agent a lock-up letter in the form of this Letter Agreement, (C) in the case of any transfer
or distribution pursuant to clause (a)(ii), (iii), (iv), (v) and (vi), no filing by any party (donor, donee, devisee, transferor, transferee,
distributer or distributee) under the Exchange Act, or other public announcement reporting a reduction in beneficial ownership of shares
of Common Stock shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on
a Form 5 made after the expiration of the Restricted Period referred to above) and (D) in the case of any transfer or distribution pursuant
to clauses (a)(i), (vii), (viii), (ix), (x) and (xii) it shall be a condition to such transfer that no public filing, report or announcement
shall be voluntarily made and if any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting
a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required
during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions
of such transfer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) exercise outstanding options, settle restricted stock units or
other equity awards or exercise outstanding warrants pursuant to plans described in the SEC Documents; provided that any Lock-up Securities
received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement; <U>provided</U> that if the
undersigned is required to make any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement during
the Restricted Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described
in this clause and that the shares of Common Stock received upon the exercise or settlement, as applicable, of the stock option, warrant
or restricted stock unit or other right or vesting event are subject to this Letter Agreement, and no public filing, report or announcement
shall be voluntarily made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) convert outstanding preferred stock into shares of Common Stock;
provided that any such shares of Common Stock received upon such conversion shall be subject to the terms of this Letter Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) establish trading plans pursuant to Rule 10b5-1 under the Exchange
Act (&ldquo;10b5-1 Trading Plans&rdquo;) for the transfer of shares of Lock-Up Securities; <U>provided</U> that (1) such plans do not
provide for the transfer of Lock-Up Securities during the Restricted Period and (2) no filing by any party under the Exchange Act or other
public announcement shall be made voluntarily during the Restricted Period in connection with such trading plan and if any such filing
or public announcement shall be legally required during the Restricted Period, such filing or public announcement shall clearly indicate
therein that that none of the securities subject to such plan may be transferred, sold, or otherwise disposed of pursuant to such plan
until after the expiration of the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the undersigned is not a natural person, the undersigned represents
and warrants that no single natural person, entity or &ldquo;group&rdquo; (within the meaning of Section 13(d)(3) of the Exchange Act)
other than a natural person, entity or &ldquo;group&rdquo; (as described above) that has executed a Letter Agreement in substantially
the same form as this Letter Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50%
or more of the voting power, in the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the undersigned is an officer or director of the Company, the undersigned
further agrees that the foregoing provisions shall be equally applicable to any Company-directed Securities the undersigned may purchase
in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the undersigned is an officer or director of the Company, (i) the
Agent agrees that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection
with a transfer of shares of Lock-Up Securities, the Agent will notify the Company of the impending release or waiver, and (ii) the Company
has agreed in the Placement Agency Agreement to announce the impending release or waiver through a major news service at least two business
days before the effective date of the release or waiver. Any release or waiver granted by the Agent hereunder to any such officer or director
shall only be effective two business days after the publication date of such announcement. The provisions of this paragraph will not apply
if (a) the release or waiver is effected solely to permit a transfer not for consideration or that is to an immediate family member as
defined in FINRA Rule 5130(i)(5) and (b) the transferee has agreed in writing to be bound by the same terms described in this Letter Agreement
to the extent and for the duration that such terms remain in effect at the time of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In furtherance of the foregoing, the Company, and any duly appointed
transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer
of securities if such transfer would constitute a violation or breach of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned hereby represents and warrants that the undersigned
has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations
of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned acknowledges and agrees that the Agent has not provided
any recommendation or investment advice nor has the Agent solicited any action from the undersigned with respect to the Offering of the
Securities and the undersigned has consulted its own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.
The undersigned further acknowledges and agrees that, although the Agent may be required or choose to provide certain Regulation Best
Interest and Form CRS disclosures to you in connection with the Offering, the Agent is not making a recommendation to you to enter into
this Letter Agreement and nothing set forth in such disclosures is intended to suggest that the Agent is making such a recommendation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned understands that, (i) if the Placement Agency Agreement
does not become effective by March 31, 2026, (ii) if the Placement Agency Agreement (other than the provisions thereof which survive
termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold in the Offering, or (iii)
the Company notifies the Agent in writing prior to the execution of the Placement Agency Agreement that it does not intend to proceed
with the Offering, the Letter Agreement shall automatically terminate and be of no further force or effect and undersigned shall be released
from all obligations under this Letter Agreement. The undersigned understands that the Agent is entering into the Placement Agency Agreement
and proceeding with the Offering in reliance upon this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned hereby consents to receipt of this Letter Agreement
in electronic form and understands and agrees that this Letter Agreement may be signed electronically. In the event that any signature
is delivered by facsimile transmission, electronic mail, or otherwise by electronic transmission (including any electronic signature complying
with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) evidencing an intent to sign this Letter Agreement, such facsimile
transmission, electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the
same force and effect as if such signature were an original. Execution and delivery of this Letter Agreement by facsimile transmission,
electronic mail or other electronic transmission is legal, valid and binding for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Letter Agreement and any claim, controversy or dispute arising
under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <td>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name of Security Holder <I>(Print exact name)</I></TD></TR>
  <TR>
    <td style="width: 60%">&nbsp;</TD>
    <td style="width: 3%">&nbsp;</TD>
    <td style="width: 37%">&nbsp;</TD></TR>
  <TR>
    <td>&nbsp;</TD>
    <td style="vertical-align: top; font-size: 10pt">By:</TD>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <td>&nbsp;</TD>
    <td>&nbsp;</TD>
    <td style="font-size: 10pt">Signature</TD></TR>
  <TR>
    <td>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">If not signing in an individual capacity:</TD></TR>
  <TR>
    <td>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name of Authorized Signatory <I>(Print)</I></TD></TR>
  <TR>
    <td>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Title of Authorized Signatory <I>(Print)</I></TD></TR>
  <TR>
    <td>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <td>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">A-5</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ea028345601ex99-1.htm
<DESCRIPTION>PRESS RELEASE DATED MARCH 25, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Health In Tech Announces $7.0 Million Private Placement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stuart, FL., March 25, 2026 /PRNewswire/ &mdash; Health In Tech, Inc.
(Nasdaq: HIT) (&ldquo;Health In Tech&rdquo; or the &ldquo;Company&rdquo;), an AI-enabled InsurTech platform company, today announced that
it has entered into a securities purchase agreement for a private investment in public equity financing (the &ldquo;PIPE&rdquo;) that
is expected to result in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses. The
PIPE is expected to close on or about March 27, 2026, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the securities purchase agreement, at the
closing of the PIPE, Health In Tech will issue an aggregate of 5,600,000 shares of common stock at a price of $1.25 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Craig-Hallum Capital Group LLC acted as the sole placement agent for
the PIPE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to use the net proceeds from the PIPE to expand
sales distribution, advance technology development, support new product development, and for general corporate purposes and working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities described above are being offered in a private placement
under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and/or Regulation D promulgated thereunder,
and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the PIPE
may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from
the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement
with the PIPE investors, the Company has agreed to file a resale registration statement with the Securities and Exchange Commission registering
the resale of the shares of common stock described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or a solicitation
of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or
other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Use of Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements in this press release are forward-looking statements
for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements
may include estimates or expectations about Health In Tech&rsquo;s possible or assumed operational results, financial condition, business strategies
and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking
statements can be identified by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;design,&rdquo; &ldquo;target,&rdquo;
&ldquo;aim,&rdquo; &ldquo;hope,&rdquo; &ldquo;expect,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;goal,&rdquo;
or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech&rsquo;s
future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech&rsquo;s actual
results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements
because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech&rsquo;s control
and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement
reflects Health In Tech&rsquo;s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions
relating to Health In Tech&rsquo;s operations, results of operations, growth strategy and liquidity. Health In Tech undertakes no obligation
to update any forward-looking statements, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Health In Tech&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Health In Tech, Inc. (Nasdaq: &ldquo;HIT&rdquo;)
is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through
vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales
and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs) and third-party administrators (&ldquo;TPAs&rdquo;).
Health In Tech&rsquo;s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for
employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims
administration and reporting integration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Health In Tech Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ir@healthintech.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Equity Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kalle Ahl, CFA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T: (303) 953-9878</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">kahl@theequitygroup.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Devin Sullivan, Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">dsullivan@theequitygroup.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>hit-20260325.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaOBSaPtyJ1x+YkxuG9/fTmafy8hcPTeYy/fTP/WkRQL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:HIT="http://healthintech.com/20260325" elementFormDefault="qualified" targetNamespace="http://healthintech.com/20260325">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://healthintech.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="hit-20260325_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="hit-20260325_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>hit-20260325_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>hit-20260325_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="hit-20260325.xsd#Cover" roleURI="http://healthintech.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://healthintech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 25, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 25,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Health In Tech, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002019505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-3545722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">701 S. Colorado Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Stuart<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">373-0333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HIT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0283456-8k_health.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://healthintech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0283456-8k_health.htm">ea0283456-8k_health.htm</File>
    <File>hit-20260325.xsd</File>
    <File>hit-20260325_lab.xml</File>
    <File>hit-20260325_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0283456-8k_health.htm": {
   "nsprefix": "HIT",
   "nsuri": "http://healthintech.com/20260325",
   "dts": {
    "inline": {
     "local": [
      "ea0283456-8k_health.htm"
     ]
    },
    "schema": {
     "local": [
      "hit-20260325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "hit-20260325_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hit-20260325_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://healthintech.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283456-8k_health.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283456-8k_health.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://healthintech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001213900-26-034716-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-034716-xbrl.zip
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MP29>PP=\+S)=GQX\DS]#2S@"(7JXR[Y:Y=F,+*HWR6W=M_BPF][#80.3>=&
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MGJ;5('OWD3HP5F'-R.Y-*%J0IUI'>)^9:8=7=#+0 >5P/26MK+>L03XBL\5
M"RX05E/2AC0YAO%(.A8-S"HR:M&TPQK*#.O 8<HBSUH]$',T1-9[SST% 5-0
M>V>>#U!QX85+V%/R"NEP'U4M%8;W=<WB1![:+J2$TGP1RU8'[=ZL,1XR%"<%
MJ^]M&?DF[&0M4.@ETQ_/=<9I&P:;'(MC/] 6H@ 3MT-'Y0M>12Y_U6GZ08A\
MZ?)4+C97TIW'H[XC@7B+S<;?61/W@M1\LX/4A)":;W:0FC^5D$]FWF0^8FW
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MW7(0-<A ML:/?=.6/2[LR1 M9YK!YF36IF0V9B4\3FH6#+[IY*.DYX^P+-;
M=]LDRF"15K-,_*GE*B\W::K@Q!4'K?Q=6TLB<$*Y,%KEU.HZ")L-[Q0T\N1Y
M[$ZCV^7*)><N>]$><%LL&#F)6!6<&G0':!RLLEJ_A:>@'R<VV]<(43&O'PSO
M!&X+VHD+-FTGV!Z8<-"I%UW*3UD="\).U/O48)2B(;=$'^_ ;L=BV4:,Q [>
M118X=F!K\'J0IT[#5@% $^FSP17*:P[B@?';N')6DEP8$JA\;/)SG31UB7TZ
M;<">_3)OY\8N.%8%>4%>HR9CAG+T#-TJ:2%'*M/'K2^QNIRC;]RI=Z-.F O
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M-*#88/77E:N9/;(<86E>I\RJ*S 74=A,*591I0,>$2Y[,M'F*6C<"3:@1G"
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M![;8!MN;(AM8JD,V@^%,E%X*23MJU]6VN;^"[O%MIZ.O0SS>F%G=^UY&Y+7
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MX#HW94U%)Z_)QJT0[89O6'L8HL?@!E1O&G?1V(04"]I I[0+[+T7MKN>"J<
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M223K*S7FG<R+M&1^Y' @KKS!9*[%JM&N'L'C/EUD^)X3/3E?/U$;%/?P4<+
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M=(HFJ@E=R*[A]B(;YM$4H2)6PX038'Y*:U;!Z5 ^,:JJU$B,]QDM4$\HC_3
MAGA!UFMY[QY S#)>]H_]R"*OH1 5O*1G2)JH:2K83F!-<G5"1]7&1$$I>AFJ
M<Q!3#=J7TWR,M =4IHY[KOQ&*]"!V#,O9\"*X?9K2G4Q2PW]?C+!_$[>&$>
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M*?CK%?L U' UXV(?X<;'&[D;2MJ4"R(#=(:ME@/KP@*KZ%1&_1?V2]/N.)$
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MZ/W<[9\>]P;9V8OL=?=E+PQ-[.^=]%Z,LN<GW=-_DO;HL/_RM#MZ,^C1IU]
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MWHM>^J\_9&=XO'>N[PD0?WU!U3J?KW3FX?.SXW<_P0^O1C^?_/3_4$L#!!0
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M\-E -.D1"B:P>3R[[J2"!]!U*N(_E@F:9_#Q$1SK))5;N82A%&)"?1['"_M
M&"=^<1*GT25=;E  P02>,<:GE<NT0JT<!6<Y&%N9W-DE?"&_@"4"K3)/RA('
M,4[S<@EW/B]8,,"WSY8I&V/T=%#ORZI,)GQ@BC@J\RP:I3&865E5Y*G1_J*I
MMK?4G74__EM1XAK1;<=O)&#0CF$4<3&&=4DO]8/C*1[%$NT],BFR/( !P=!
M0+$X>?3X^>MWQZ?Z--PO0>#QD0 I>/+Q_7XU>_XC_O?YC_A9.$#C*(VS253
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M@AU@YRE?5D&:@%]"'T3'3#U10JGTV))\JR2#/9OS0Q<8O<R790H^6BZ>#=G
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MIHB8SA=L;Y%N'Q%*KX#3"I>_P/V,/X]G47;&YPT.#@@?_/O4O)MC+J2MQB!
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M(FMT*I-254HK4)>.[C9(>*FID'R=W 5?C^;L=*-%1^<9G^5X#C&GPM%L'K0
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M5=M;MQLOL>6+ZX5#MK<ZXB&@2]]*',0+,[3JRJ"N*I5K]'3-L(. ;OKB#LJ
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M@-1:'QDDE+]X')OS,#6P$8\Q(<TT#A;D1=Y2NPN*58V8?$VD:IM2S6T?1H(
M24#[R!UAX*/$<J=Y/C:SLMU7)/9-<764(M$E#=6$V%ONNB2(*"UHK@YSZ%$F
M LS-J!)_:)H:XF0.PY.3*V45';<2[UVK8]H&B)5+&'HM:SR$JK3Y0V"1(HH5
MK!.,^@*K0H0QUE!=IO$YAL4POE_18I"0Q-:K]#9V&IH3XD59>TI6MOI"0;?'
M"7%W4+IS3IMHND/;&9JR-F/#Q?V'I+M47)0-]NN!W'4"<KTD;BA-FY$%,OH4
M9TPI0<"YD$232O#I9![EFK@1?"UFK<.91:O6L;%:"BJ84@*[->C(H^+^E.47
M5,(3$K4L@3?\05"<<X&G>4GQ;N+:*XK8-#.0M)<3_&%[6H?/1O>=$N^'Z: #
M56/D 'CJ7!C:5LMA4*. =+45);I0*!#(,FA:+IE7R5@OOG"X5%L<V@QS&XFP
MZ+J0M>2';\NHKW*G/$<?J@"4TEO,*F%O(.W2MUD#JW)\F+#UQ*\_@SJ@DEI+
MH?FW48/[I^Y>24(9#BV>*!M4XGV4@ 4^BVTF*S63J5,W=:+&&@P55"X%T7Q1
M"%L;@,R-J!6D;5O,C.Y67+M$OOH4#=&2,!*5(1)+!YI7NDN\M]&+)'.XB:C6
M.',PCEF\8OSIK(@6LZ[LN#=_Q>%#TM-!M[N0P%W9\Z"1/+=PX3O-GFL#@H78
M]M9-9\][]5:_DAIB%:=+LL.1O4IJO2UGWK&?&W%!XL*EBPE9X2U69)11#<SD
M'2H,SB6.,L-D%UPPSR9/&R8"[ABR>W'LN>&G<I3]1NDHOY%:^"=4"_]K4H[!
MTHVR.%^6-UL)_P77X=H%\!_0LL+3 &=$\A[GUA#&2!S<]7KY7Z$[*QF;C45(
M4I@ .%4:K2[)4QCD&DT.6886OVB;?_N7@F%A<1L?.<6H,.T" JR(,L&X(CD&
MRNOVX>C@%#7HN:1HORWU;65 ES*M<5M1H@R@[6T"P/89L@+;4LZ4/>''2XGV
M@ L45UA::E2+,SP,DQRX&7\L.14T1U7'6M;XQUS#[%FR3M?H_4XJ?U_Y^:6@
M)^H!08:$<^L\$W91 [<MV]S1<@X;F;EM*^CG4DCI\/A""[?@M!3CB BL1]MS
M$9DZ(Y=AHQ0G\H5,+JF)+)P"7KN16[*-[J+2@>,\>)^<G5V.HO$GV.O,0]*5
MS]"QH7YVI/BSX#7SPQ&#>P?H#EETI &&/NJ9P:GS59$"X<O -"(9&&??@"15
M 1C;(-$B&N,WK#UMN)I16IBTNJ91\^]:+WB\#-SKZ\:1)@WM*C=KM U1+W$A
MFE"_I<E@&1P2;UIP9+IL#R+DT)R*S<#+TNP\-#04G%$/T4=AN%'C>BN$3B N
M^SLX K")\5N6'U.SIG2T^_7LFR=XTMQBV1Z)>GLHA2GT@XI/R5)X-A:3UGR"
MT3A5)HJ5ITTN%B132S&@1%6M0097JNQ<FUQA00C[P JB=0P;(;)>LG1WDRRM
M)4MW-\G2;^J8(S#Z%17V@CQ8HMQYY5I*[ 0O+DFK16-N(-1;4A%VF7PA^^FF
MU)V,-,D5VC:A-5:.SBYF\OM/";%9EF-P2#N8!0+=2,DG;:.>1!1<972OFW^]
MH49O;U+#$M6A9UAY<9M(8H7RJTDT\)KK_"W(NN:JM/1"\HA65?T':M:D<IXS
MQ69<]4<\L7W-XLG0]?V@)DH]?9M&5&S7VJ2)M7=GEZ;@>DV:Y/00QG=LP_T&
M\Z.8UJ6-"^55M7V%3_>:JJ@])H7J[W-/W,C!]15WN-^YR7H5JIJ36S!M%"GE
M7P^<X4.AI-_0N2G$ZO27K]N9;2XU?=801(=TW"1\+4<<?I9/.,7D54$1IQ0.
MY(('P@S:KEOZ!*$7V#:P=!)*O5H #NI]".S/+ ;.(DKMB5'WGL@D8-D:M+5<
M4ZQ=!'C'XP<[NS]0ZBTO[!6CQ'"^K&P!;<?1':!;*M5B3.:+5*\FU1+R^BF
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M23O/N69MF<E%Q7 ,I\681E]U&R /7HVV=,-EQUX-6/M <IRZR?F%+=GPD+A
M%\8_+MB B(1B)13'C@.B,J/(9&R]:+;P8O+#I(%(4G3V^Q/\ @4OIDDFC)_,
MGQ-A!)W:<])50')F=I/&,\O*1NJ)\@XCC'%5_ +[&RG^BP2D4.][P,S&M>.
M.;S6\P &@IP @B/#V5LL^5%LI0ARD;>=*IJH-+*FEA.#F*B(Y-9YTM9:<^>
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M>Q:&3(0!J#)U3W$[C@[;AUC[A'2,D[_=JX5T>[BH6L=/F1(5%5P#;6PY=,3
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MXX!HEYF@$Z&*6:!8S%<"OY17O &7?)5)'FO'9 $<AR1-B&AUNK%K-L+V&[\
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MN%IR:,B(K1!]G"R!.VERQ(34-1Q988ZR[01>0<[&.*A %"/1:88R.*<FD#)
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MD>K@SUM\>^OI=I?RE\L;CN!IK#[9?_8L(VAS'$<)7VL9Z]M7VU^QBYA\$%5
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M-UV+3V*SVB3^6N&,B"W_!5!+ P04    "  6@7I<XE0I/%L'  #;5P  %
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M2(B %4!#@IB?O@@%SN,"F:9N,Y&,GT8S*UK?929_AZGU+_C0(%@.&AK,39P
MX4AW0?KG1B^:7*\>Z(0JMTSAD2[-M6WH*7Q3!"@.C0_J&X7 &$K"=-$^TG5K
M#[C7U!;?N%_N5:SVR/]02P$"% ,4    "  6@7I<S:!\E8P?  "XG@  %P
M            @ $     96$P,C@S-#4V+3AK7VAE86QT:"YH=&U02P$"% ,4
M    "  6@7I<%=BXX\*;  #G4 , %0              @ '!'P  96$P,C@S
M-#4V,#%E>#$P+3$N:'1M4$L! A0#%     @ %H%Z7$+8/F$V6@  U#8" !4
M             ( !MKL  &5A,#(X,S0U-C Q97@Q,"TR+FAT;5!+ 0(4 Q0
M   ( !:!>EQG$%3/&CL  ',: 0 5              "  1\6 0!E83 R.#,T
M-38P,65X,3 M,RYH=&U02P$"% ,4    "  6@7I<9:H.E=L)  #+)   %0
M            @ %L40$ 96$P,C@S-#4V,#%E>#DY+3$N:'1M4$L! A0#%
M  @ %H%Z7$H$&GTH P  ZPL  !               ( !>EL! &AI="TR,#(V
M,#,R-2YX<V102P$"% ,4    "  6@7I<8=)W_/T*  !_A@  %
M    @ '07@$ :&ET+3(P,C8P,S(U7VQA8BYX;6Q02P$"% ,4    "  6@7I<
MXE0I/%L'  #;5P  %               @ '_:0$ :&ET+3(P,C8P,S(U7W!R
;92YX;6Q02P4&      @ "  3 @  C'$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ea0283456-8k_health_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hit-20260325.xsd" xlink:type="simple"/>
    <context id="AsOf2026-03-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002019505</identifier>
        </entity>
        <period>
            <startDate>2026-03-25</startDate>
            <endDate>2026-03-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-03-25" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-03-25" id="Fact000004">0002019505</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-03-25" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-03-25" id="Fact000010">2026-03-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-03-25" id="Fact000011">Health In Tech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-03-25" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-03-25" id="Fact000013">001-42449</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-03-25" id="Fact000014">87-3545722</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-03-25" id="Fact000015">701 S. Colorado Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-03-25" id="Fact000016">Suite 1</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-03-25" id="Fact000017">Stuart</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-03-25" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-03-25" id="Fact000019">34994</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-03-25" id="Fact000020">888</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-03-25" id="Fact000021">373-0333</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-03-25" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-03-25" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-03-25" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-03-25" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-03-25" id="Fact000026">Class A Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-03-25" id="Fact000027">HIT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-03-25" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-03-25" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-03-25" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
